



(11) **EP 2 555 807 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Drawings**  
**Drawing(s) replaced or added**

(51) Int Cl.:  
**A61L 27/14** <sup>(2006.01)</sup>      **A61L 27/38** <sup>(2006.01)</sup>  
**A61K 35/12** <sup>(2015.01)</sup>      **A61K 35/39** <sup>(2015.01)</sup>  
**A61L 27/18** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**08.12.2021 Bulletin 2021/49**

(86) International application number:  
**PCT/US2011/030775**

(45) Date of publication and mention of the grant of the patent:  
**31.07.2019 Bulletin 2019/31**

(87) International publication number:  
**WO 2011/126921 (13.10.2011 Gazette 2011/41)**

(21) Application number: **11714194.5**

(22) Date of filing: **31.03.2011**

(54) **TEMPLATED ISLET CELLS AND SMALL ISLET CELL CLUSTERS FOR DIABETES TREATMENT**

TEMPLATE-INSELZELLEN UND KLEINE INSELZELLCLUSTER ZUR BEHANDLUNG VON DIABETES

ILOTS DE LANGERHANS À MATRICE ET PETITS AMAS D'ÎLOTS DE LANGERHANS POUR LE TRAITEMENT DU DIABÈTE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(74) Representative: **Haseltine Lake Kempner LLP**  
**Redcliff Quay**  
**120 Redcliff Street**  
**Bristol BS1 6HU (GB)**

(30) Priority: **06.04.2010 US 798529**

(56) References cited:  
**EP-A1- 2 286 822**      **WO-A2-03/044164**  
**US-A1- 2008 103 606**

(43) Date of publication of application:  
**13.02.2013 Bulletin 2013/07**

(73) Proprietor: **University of Kansas**  
**Lawrence, KS 66045 (US)**

- **CHOI Y ET AL: "Controlled-size embryoid body formation in concave microwell arrays", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 15, 5 March 2010 (2010-03-05), pages 4296-4303, XP026971506, ISSN: 0142-9612 [retrieved on 2010-03-05]**
- **Cheryl A. Bodnar ET AL: "Characterization of human islet-like structures generated from pancreatic precursor cells in culture", BIOTECHNOLOGY AND BIOENGINEERING., vol. 93, no. 5, 5 April 2006 (2006-04-05), pages 980-988, XP055233320, US ISSN: 0006-3592, DOI: 10.1002/bit.20801**

(72) Inventors:

- **BERKLAND, Cory**  
**Lawrence, KS 66047 (US)**
- **STEHNO-BITTEL, Lisa, A.**  
**Kansas City, KS 66160 (US)**
- **SIAHAAN, Teruna**  
**Lawrence, KS 66047 (US)**
- **RAMACHANDRAN, Karthik**  
**Lawrence, KS 66046 (US)**

**EP 2 555 807 B9**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

**Description**

## FIELD OF THE INVENTION

5 **[0001]** The present invention generally relates to compositions and processes for creating viable islets cells, islets, and small islet cell clusters.

## DESCRIPTION OF RELATED ART

10 **[0002]** The rise in cases of diabetes mellitus in the United States has been called an epidemic. Diabetes is the third leading cause of death by disease and rivals heart disease and cancer as a major killer of United States citizens. For unexplained reasons, the occurrence of type 1 diabetes is increasing worldwide, and the age of onset has decreased by three to five years over the past decade so that many children now develop diabetes prior to entering school. The result is that more people with diabetes will spend a larger percentage of their life at risk for developing the chronic complications related to type 1 diabetes. Since the risk for development of most of the chronic complications associated with diabetes is related to glycemic control, significant attention is directed toward novel therapies, such as islet trans-  
15 plantation, to improve glycemic control.

**[0003]** Islet transplants were first attempted in the 1980s. Initial success rates for islet transplantation in humans were disappointing with only 5% of patients receiving transplants achieving partial function. See Sutherland et al., Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota, *Am. J. Surg.* 166: 456491 (1993). Amid the failures were isolated success stories of individuals achieving prolonged reversal of their diabetes for a 1 to 2 year period, which encouraged researchers to continue this approach to treatment of diabetes. In 2000, islet transplantations were performed successfully on seven patients with diabetes using a suppression regimen that omitted glucocorticoids, now referred to as the Edmonton protocol. See Ridgway et al., Pancreatic islet cell trans-  
20 plantation: progress in the clinical setting, *Treat. Endocrinol.* 2 (3): 173-189 (2003). Thus, islet transplantation outcomes have improved markedly. See Shapiro et al., Clinical results after islet transplantation, *J. Investig. Med.* 49(6): 559-562 (2001); Balamurugan et al., Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes, *Pancreas* 32(3): 231243 (2006). Yet, regardless of the optimism generated by these results, barriers to the use of islet transplantation as a practical treatment for diabetes still exist, with one barrier being the limited number of donor organs considering that most individuals require multiple transplants to achieve insulin independence.  
25

**[0004]** Many factors may have an effect on transplantation success, including the physical characteristics of the islet. About 20 years ago, researchers described in detail the size and shape of islets and determined a method for estimating islet volume. See Bonnevie-Nielsen et al., Pancreatic islet volume distribution: direct measurement in preparations stained by perfusion in situ, *Acta Endocrinol. (Copenh)* 105(3): 379-84 (1984). For many years, large islets have tradi-  
30 tionally been considered desirable by transplant sites for several reasons: (1) the presence of large islets is considered a hallmark of a good pancreatic digestion, since islets can be fragmented by excessive digestion, and (2) volume is used to determine the minimal number of islets needed for transplantation, and because doubling an islet's diameter is equivalent to an eight-fold increase in its volume, large islets make a major contribution to the number of islet equivalents in a preparation.  
35

**[0005]** In recent years, researchers have modeled the transport of oxygen, glucose, and insulin through the islet. See Dulong et al., Contributions of a finite element model for the geometric optimization of an implantable bioartificial pancreas, *Artif. Organs* 26(7): 583-9 (2002). Limited transport of oxygen can propagate cell death in the core of islets if the rate of oxygen consumption by peripheral cells exceeds the rate of oxygen diffusion into the islet. For example, recent studies indicate that larger islets exhibit increased necrosis when exposed to hypoxic conditions. Indeed, nearly all beta cells  
40 died when islet diameter exceeded 100-150  $\mu\text{m}$ . See Giuliana et al., Central necrosis in isolated hypoxic human pancreatic islets; evidence for postisolation ischemia, *Cell Transplantation* 147 67-76 (2005); MacGregor et al., Small rat islets are superior to large islets in in vitro function and in transplantation outcomes, *Am. J. Physiol. Endocrinol. Metab.* 290(5): E771-779 (2006). The resulting oxidative stress can aggravate apoptosis and immune response upon transplantation. See Bottino et al., Response of human islets to isolation stress and the effect of antioxidant treatment, *Diabetes* 53(10): 2559-68 (2004). Even in cases where cell death has not occurred, a decreased metabolic rate in the islet core is probable.  
45

**[0006]** Retarded transport of glucose and insulin also diminishes the functionality of pancreatic islets. The glucose gradient within an islet causes peripheral cells to contact much higher concentrations of glucose than those contained in the islet core. See Kauri et al., Direct measurement of glucose gradients and mass transport within islets of Langerhans, *Biochem. Biophys. Res. Commun.* 304(2): 371-7 (2003). The shape of this gradient is directly related to the diameter  
50 of the islet and the rate of glucose metabolism. Increasing islet diameter increases this diffusional and consumptive barrier in all planes within the islet.

**[0007]** To find another source of insulin-producing beta cells, there have also been efforts to culture beta cells *in vitro*. These methods have focused on the culturing of beta cells from fetal tissue or deriving such cells from islet-producing

stem cells or progenitor cells. See, e.g. Peck et al., U.S. Patent No. 6,703,017; Brothers, WO 93/00411 (1993); Neilsen, WO 86/01530 (1986); Zayas, EP 0363125 (1990); Bone et al., Microcarriers; A New Approach to Pancreatic Islet Cell Culture, In Vitro Vol. 18, No. 2 February (1982). Unfortunately, such techniques are generally time consuming and require the availability of rare fetal tissue or stem cells as their source and result in a confluent monolayer of cultured beta cells.

Thus, there remains a need to create viable islets cells using more efficient, available, and reliable techniques.

**[0008]** US 2008/103606 relates to an implantable biomaterial scaffold having islet cells or small islet cell clusters attached thereto in a multilayer. The cells are derived by enzymatic dispersion and/or calcium depletion of large adult intact islets. WO 03/044164 relates to a cell support system useful for the implantation of living cells in a subject comprising a solid substrate, typically formed from a biologically inert material and having a textured surface portion, with the textured surface portion defining a plurality of recessed cavities therein. Choi et al., Biomaterials, 2010, 31(15), pages 4296 - 4303 discloses the use of engineered concave microwell arrays to regulate the size and shape of embryoid bodies (EBs)-cell aggregate intermediates derived from ES cells. It was found that ES cell-derived cardiogenesis and neurogenesis were regulated by EB size, showing that larger concave microwell arrays induced more neuronal and cardiomyocyte differentiation than did smaller microwell arrays. EP 2286822 relates to a scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern.

**[0009]** In an attempt to overcome the diffusional barrier encountered in the architecture of large intact islets, various attempts were made by the present inventors to grow multiple layers of islet cells on polymer microspheres for implantation. The microspheres shown in FIG. 1A were engineered to be within the size range of intact islets. By attaching beta cells to the outer surface of the microsphere, it was theorized that there should be little or no cell death due to diffusional barriers. Multiple attempts were made using different culture environments to optimize the attachment of the cells to the microspheres, including the use of extremely high density of cells in suspension. However, this method quickly depleted the media of nutrients and the cell survival was poor. Other techniques included cells that were "dripped" slowly onto the microspheres to increase the physical interaction of the cells with the microsphere or co-culturing the cells and microspheres in a microgravity chamber for several days. While some beta cells would attach to the polymer microspheres, their distribution was uneven, and multiple layers of attached cells were never consistently achieved (FIG. 1B).

#### BRIEF SUMMARY

**[0010]** Disclosed herein is an implantable device comprising a substantially planar scaffold comprised of a biomaterial having a major surface, and individual islet cells or small islet cell clusters attached in a multilayer to the surface of the biomaterial scaffold. The individual islet cells or small islet cell clusters are preferably derived from adult intact islets. Cell adhesion molecules (e.g. integrins, cadherins, selectins, and immunoglobulins) may be attached to the scaffold to facilitate attachment of individual islet cells or small islet cell clusters to the scaffold. Further, one or more angiogenesis factors, immunosuppressive agents (including autoimmune suppressors), antibiotics, antioxidants, anti-cytokines, or anti-endotoxins may be controllably released from the scaffold to improve viability of the islet cells and small islet cell clusters.

**[0011]** The biomaterial scaffold may be a flexible biomaterial, and may be comprised of a biocompatible and/or biodegradable polymer, such as poly(DL-lactide-co-glycolide) (PLG), polylactic acid (PLA), or poly(lactic-co-glycolic acid) (PLGA).

**[0012]** The multilayer may comprise a combination of insulin-producing beta cells and other islet cell types. The multilayer is preferably about 1-2 to 5 cells thick, and forms a multilayer about 10 to 50  $\mu\text{m}$  thick. The multilayer preferably has a substantially uniform thickness such that the cell thickness varies by no more than 1 to 2 cells across the surface of the biomaterial scaffold.

**[0013]** The individual islet cells or small islet cell clusters may be derived from intact adult islets using enzymatic digestion and/or culturing in a calcium-depleted media.

**[0014]** Also disclosed herein is a method of forming the implantable device. In particular, techniques for deriving individual islet cells or small islet cell clusters from intact islets are provided (e.g. enzymatic digestion, calcium depletion, or a combination thereof). In addition, methods for attaching the individual islet cells and/or small islet cell clusters are provided, which include centrifuging from a suspension of cells and the use of cell adhesion molecules to improve attachment to the scaffold surface.

**[0015]** Also disclosed herein is a method of using the implantable devices as a treatment for diabetes. Methods for implanting the devices, and techniques for treatment of diabetes are described.

These disclosures are not in accordance with the appended claims. The appended claims define the presently claimed invention.

**[0016]** In one embodiment, the invention is a surface for culturing cells as defined in claim 1.

**[0017]** In another embodiment, the invention is a device for culturing cells comprising the surface described above and additionally comprising a system for holding the planar surface. The system forms a bottom surface and an interior

side wall surface and an interior volume, the bottom and side walls being substantially tight to liquids. When the device is used, cells and culture medium are distributed into the interior volume. In a preferred embodiment, the cells are islet cells. In another preferred embodiment, the cells are non-islet cells selected from the group consisting of stem cells, cell culture lines, fresh-dispersed or primary cells. In another preferred embodiment, the cells are islet cells and the divots are 100  $\mu\text{m}$  ( $\pm 20\%$ ) in diameter and 60  $\mu\text{m}$  ( $\pm 20\%$ ) in depth.

**[0018]** In another embodiment, the invention is a method for culturing cells as defined in claim 6.

**[0019]** In another preferred embodiment, the cells have been dispersed from an islet culture and non-native molecules are engineered into the resulting small islets. In another preferred embodiment, the non-islet cells are selected from the group consisting of stem cells, cell culture lines, fresh-dispersed or primary cells.

**[0020]** Also disclosed herein is a method for testing a plurality of cell samples for response to an introduced chemical comprising the steps of (a) culturing cells in a device comprising a plurality of divots, wherein each divot is between 100 and 200  $\mu\text{m}$  in diameter ( $\pm 10\%$ ) and 50 and 150  $\mu\text{m}$  in depth ( $\pm 10\%$ ), (b) introducing a test chemical to each divot, and (c) analyzing the response of the cells to the test chemical.

This method may use the surface and/or method defined in the appended claims.

**[0021]** Also disclosed herein is an isolated population of islets wherein at least 80% of all islets are below 90  $\mu\text{m}$  in diameter and wherein the islets have low diffusion barriers relative to native large islets. Preferably, the islets have a high cell viability

relative to native small and large islets, and islet insulin production is characterized by levels that are greater than 10 times more than native isolated islets. Preferably, a majority of islets are spherical. Preferably, the islets comprise pancreatic alpha cells, pancreatic beta cells and pancreatic delta cells. Preferably, at least 85% of the islets are viable. Preferably, at least 80% of all islets are less than 50  $\mu\text{m}$  in diameter. Preferably, at least 50% of the islets are less than 37  $\mu\text{m}$  in diameter. Preferably, the islet beta cells produce insulin in greater amounts compared to beta cells isolated from native small islet or native large islets.

This disclosure is not in accordance with the appended claims.

## BRIEF DESCRIPTION OF THE DRAWINGS

### [0022]

FIGS. 1 A and B illustrate previous attempts to grow beta cells on microspherical polymers for implantation into a patient. In the images, an uneven distribution of cells are shown attached to a PLGA microsphere coated with chitosan polymer. A partial monolayer of cells was all that could be obtained after long-term incubation with the beta cells.

FIG. 2 is a graph that compares the cell viability for cultured large rat islets (greater than 125  $\mu\text{m}$ ), small islets (less than 125  $\mu\text{m}$ ), and dispersed beta cells as a function of time. The decreased viability of large islets is statistically significant ( $p < 0.05$ ) beyond day 3.

FIGS. 3A and B summarize the results of transplantation of small islets (less than 125  $\mu\text{m}$ ) or large islets (greater than 125  $\mu\text{m}$ ) into diabetic rats. A successful return to euglycemia was observed about 80% of the time when small islets were used, but transplants were unsuccessful in restoring normal plasma glucose levels when the large islets were transplanted. This can be best illustrated by showing the plasma glucose level of the animal in each group 60 days after transplantation. The animals receiving large islets remained hyperglycemic after the transplant, while the rats receiving small islets were euglycemic. \* indicates significant difference of 0.01.

FIG. 4 is an islet graft removed from the kidney capsule about eight weeks after transplantation and immunolabeled for insulin. The image on the left panel shows relatively more insulin immunolabeling (red) and an established capillary network in a graft using small islets (less than 125  $\mu\text{m}$ ). In contrast, grafts of large islets (greater than 125  $\mu\text{m}$ ) showed little insulin immunolabeling and significant fibrosis (right panel). The images are representative from four different animals.

FIG. 5 shows a rat small islet cell cluster stained with dithizone to identify beta cells. Because the confocal aperture was set for an extremely thin Z section, the cells within the subunit, but below the plane of focus, are blurry and do not appear red. However, adjustment in the confocal plane to those cells indicated that they also were clearly stained with dithizone.

FIG. 6 (panel A) shows the live/dead staining of a small islet cell cluster made from an intact adult islet using enzymatic dispersion. This small islet cell cluster is approximately 40  $\mu\text{m}$  in diameter. In the upper right panel of

FIG. 6 (panel B), a small islet cell cluster derived by cultivating an intact islet with a calcium depleted media is shown. The small islet cell cluster was unwound or opened so that media was able to surround the cells in the cluster. In FIG. 6 (panel C), a small islet cell cluster derived using both calcium depletion and enzymatic dispersion is shown. The diameter of the fragment was approximately 15  $\mu\text{m}$ . FIG. 6 (panel D) shows individual islet cells derived from a combination of calcium depletion and enzymatic digestion followed by manual pipetting. The red indicates dead cells and green cells are alive. Scale bar in panel B applies to Panels A through C.

FIG. 7 is a schematic representation of the production of a patch having a multilayer of islet cells attached thereto .

FIG. 8 shows optical micrographs of beta cell adhesion to (A) chitosan (Mw = 100 kDa) and (B) laminin. The inset shows optical and fluorescent micrographs of a beta cell on laminin with cytoch B (green) stain for actin.

FIG. 9 demonstrates the results when layering islet cells onto a polymer patch made of 50:50 ALGA-carboxyl (5.5 kDa). The patches were optically sectioned using a confocal microscope. The images were rendered to obtain the Z section slice shown. The upper panel illustrates a patch with one or two layers of cells, and additional cell layers were then added as shown. Cells were layered onto the scaffold by spinning them in a plate centrifuge at about 3500 rpm for about 10 minutes. The layers remained attached to the polymer scaffold after repeated rinsing.

FIG. 10 is a schematic depicting the general design of a micro-mold with divots. In this example PDMS is the material comprising the housing of the micro-mold and etched glass is the substrate in which the divots are etched.

FIG. 11 is a micrograph showing a top-down view of empty divots in a micro-mold; the pattern of divots depicted here is representative of micro-mold design B.

FIG. 12 is a graph generated by a profilometer illustrating the depth of a single divot and the round bottom shape of the divot.

FIG. 13 is a schematic illustrating the scaffolding utilized for micro-mold production. Components of the micro-mold and scaffolding to build the micro-mold are: [1] a large copper tube; [2] a small copper tube; [3] PDMS polymer, which comprises the system that houses the divoted surface; [4] a flat surface, such as a large square of glass wrapped in aluminum foil, used as a base upon which to build the micro-mold; [5] the vertical walls of the micro-mold housing; [6] the base of the micro-mold, shown here poured to a depth of 2 mm; and [7] the etched glass, which is the divoted substrate.

FIG. 14 is a micrograph showing islet cell reaggregation within the divots of a micro-mold on days 2 and 5.

FIG. 15 is a micrograph showing the undivoted edge of the divoted substrate adjacent to the field of divots; divots contain small reaggregating islet cells, but those cells that fell onto the undivoted surface have reaggregated into large mega-islets.

FIG. 16 is a micrograph showing live islet cells congregated at the edge of a well in a commercially available plate; reaggregation of islet cells is not spherical as in the micro-mold, and the reaggregated group of islet cells is much larger than the 90  $\mu\text{m}$  islets formed in micro-molds.

FIG. 17 A and B is a set of schematics showing two possible divot patterns for the micro-mold; Fig. 17A is a design where divots are close to one another, which would be useful when trying to maximize the number of reaggregates formed in a single micro-mold; Fig. 17 B is a design where divots are spaced further apart from one another, which would be useful when manipulating treatment of cells in individual divots.

FIG. 18 is a micrograph showing two reaggregated islets contained within a single divot.

FIG. 19 A and B is a set of micrographs showing viability staining in reaggregated islets; red indicates dead cells. Fig. 19 A shows that islets reaggregated within micro-molds contain very few dead cells, only one dead cell is stained in the upper islet, while there is no evidence of cell death in the lower islet. Fig. 19 B shows a mega-islet that formed on the undivoted surface of the micro-mold, wherein there are at least 23 dead islet cells in the confocal plane of view.

FIG. 20 is a graph comparing the viability of native small and native large islets with reaggregated islets. All islets were removed from the same rats and a portion of the isolated islets were dispersed into islet cells for reaggregation.

On day five, the reaggregated islets were removed from the micro-mold and all islets were exposed to live/dead viability stains. The percentage of live cells in the reaggregated islets was higher than that for native large or small islets.

5 FIG. 21 shows two representative islets 6 days after reaggregation in micro-mold divots that have been triple-stained to identify beta cells (green), alpha cells (red), and delta cells (blue). The upper islet measures 43 x 55  $\mu\text{m}$  in diameter (measured in X and Y directions), and the bottom islet measures 48 x 65  $\mu\text{m}$  in diameter.

10 FIG. 22 shows a 6-day reaggregated islet formed in a micro-mold divot that has been stained for insulin (green) and proinsulin (red). This islet is 45 x 54  $\mu\text{m}$  in diameter (measured in X and Y directions).

15 FIG. 23 is a graph depicting insulin secretion in three islet types exposed to different glucose conditions. Native small islets and islets reaggregated in micro-mold divots were exposed to low glucose conditions (3 mM); insulin secreted into the media was collected and quantified as indicated by the Y axis. Native small islets, native large islets and islets reaggregated in micro-mold divots were exposed to high glucose conditions (20 mM); insulin secreted into the media was collected and quantified as indicated by the Y axis.

20 FIG. 24 is a schematic flow chart illustrating the general method for using the instant micro-mold to reaggregate optimally-sized islets.

FIG. 25 is a schematic flow chart illustrating one exemplary use of the instant micro-mold for high-throughput drug testing.

25 FIG. 26 shows reaggregated islets in media containing 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D glucose (2-NBDG; 20 mM). Circles indicate location of islets. 2-NBDG, a fluorescent glucose analogue, is fully integrated into each reaggregated islet.

30 FIG. 27 shows a design for the negative stamp (made of metal or SU-8) that could be used to create the biopolymer molds. The final product would have divots similar to those created in glass molds.

35 FIG. 28 A and B illustrates the negative stamp design including labels to identify the location of each divot within a field of divots in each micro-mold. As shown in FIG. 28 A, different shapes could be designed for the divot bottom with more precision than the glass etching method. FIG. 28 B demonstrates a portion of a final biopolymer mold containing divots with distinguishing labels.

FIG. 29 A and B compares two islets of approximately the same size. FIG. 29 A is an example of a spherical reaggregated islet. FIG. 29 B depicts is a native small islet. The shape, size, and smooth capsular-like outer edge are similar for both islets.

## 40 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

### A. In General

[0023] In the case of inconsistencies, the present disclosure, including definitions, will prevail.

45 [0024] As used herein, the term "islet of Langerhans" or "islet" refers to a group of specialized cells in the pancreas that make and secrete hormones. An islet generally contains one or more of the following cell types: (1) alpha cells that make glucagon, which raises the level of glucose (sugar) in the blood; (2) beta cells that make insulin; (3) delta cells that make somatostatin which inhibits the release of numerous other hormones in the body; (4) pancreatic peptide producing PP cells; (5) D1 cells, which secrete vasoactive intestinal peptide; or (6) EC cells which secrete secretin, motilin, and substance P.

[0025] As used herein, the term "islet cell" refers to any one of the cells found in an islet. The islet cells that may be used in the present invention are preferably a combination of insulin-producing beta cells with other islet cell types.

55 [0026] As used herein, the term "small islet cell cluster", or "islet fragment" refers to a collection of islet cells bound together, usually less than about 25 islet cells in the cluster. The small islet cell cluster preferably has a morphology such that the diffusional barrier for any cell within the cluster (e.g. for nutrients, oxygen, glucose, etc.) is no more than about 7 cells. Typically, the diffusional barrier is less than about 5 cells, and may be as low as 4, 3, or 2 cells. The "small islet cell cluster" preferably comprises beta cells as the predominant cell type, and may optionally include one or more other islet cell types. The small islet cell clusters may have a variety of shapes (e.g., be generally spherical, elongated,

or otherwise asymmetrical). Examples of small islet cell clusters are shown in FIGS. 5 and 6(A), 6(B), and 6(C). The "small islet cell clusters" are preferably derived by dispersing intact larger islets isolated from a donor pancreas.

**[0027]** As used herein, the term "native islet" refers to islets derived from an animal pancreas. Native islets can be characterized as "native large islets" having a diameter of greater than 125  $\mu\text{m}$ , preferably greater than 150  $\mu\text{m}$ , or "native small islets" having a diameter of less than 125  $\mu\text{m}$ .

**[0028]** As used herein, the term "mega-islet" refers to a reaggregated islet having a diameter greater than about 300  $\mu\text{m}$ .

**[0029]** As used herein, the term "adult intact islet" refers to a native large islet or a native small islet derived from an adult mammalian pancreas, wherein the islet has not been broken apart.

**[0030]** As used herein, the term "dispersed islet cells" refers to a suspension of cells, preferably derived by disrupting large islets such that islet cells are uniformly distributed in suspension. Preferably, no less than 90% of islet cells in suspension are single cells, the remainder comprising doublets (two cells bound together) and triplets (three cells bound together), and very few larger groups of cells bound to one another.

**[0031]** As used herein, the term "reaggregated islet" refers to a collection of islet cells bound together, preferably derived by breaking down large islets into single islet cells and culturing those single islet cells together in groups to form islets. Preferably, the reaggregation of single islet cells into islets is influenced by the physical dimensions of the divots in the micro-mold. The number of individual islet cells used to form a reaggregated islet is dependent on the desired size of the islet product.

**[0032]** As used herein, the term "diffusion barrier" refers to inhibition of molecule movement from an area of high concentration (e.g., oxygen or glucose concentration outside a cell) to an area of low concentration (e.g., oxygen or glucose concentration inside a cell). Large islets exhibit relatively high diffusion barriers to oxygen, which limits their viability and utility for transplantation. Islets reaggregated in micro-molds are small relative to native large islets, and exhibit a relatively low diffusion barrier, which contributes to cell viability within reaggregated islets.

**[0033]** As used herein, the term "cell viability" refers to a measure of the amount of cells that are living or dead, based on a total cell sample. High cell viability, as defined herein, refers to a cell population in which greater than 85% of all cells are viable, preferably greater than 90-95%, and more preferably a population characterized by high cell viability contains more than 99% viable cells.

**[0034]** As used herein, materials that are intended to come into contact with biological fluids or tissues (such as by implantation or transplantation into a subject) are termed "biomaterials." It is desirable that biomaterials induce minimal reactions between the material and the physiological environment. Biomaterials are considered "biocompatible" if, after being placed in the physiological environment, there is minimal inflammatory reaction, no evidence of anaphylactic reaction, and minimal cellular growth on the biomaterial surface. Upon implantation in a host mammal, a biocompatible biomaterial does not elicit a host response sufficient to detrimentally affect the function of the microcapsule; such host responses include formation of fibrotic structures on or around the biomaterial, immunological rejection of the biomaterial, or release of toxic or pyrogenic compounds from the biomaterial into the surrounding host tissue.

**[0035]** As used herein, the term "etch" refers to a chemical process using acid to create divots in a substrate.

**[0036]** As used herein, the term "divot" means a localized well or chamber in a substrate comprising a bottom and a sidewall (i.e. a hollowed-out space, having width and depth). In one embodiment, for the reaggregation of islets a divot is less than 100  $\mu\text{m}$  in diameter and 60  $\mu\text{m}$  in depth. For example, the divot could be 80  $\mu\text{m}$  in diameter and 48  $\mu\text{m}$  in depth. In other embodiments where one wishes to reaggregate islets, the divots are between 80 - 120  $\mu\text{m}$  in diameter and 48 - 72  $\mu\text{m}$  in depth. For other purposes, such as growing mini-tumors for drug testing, the optimal divot diameter would be between 100 and 200  $\mu\text{m}$  in diameter and 60 to 100  $\mu\text{m}$  in depth.

**[0037]** As used herein, the term "divoted substrate" refers to a solid support or any material that has been modified to contain discrete individual divots.

**[0038]** As used herein, the term "micro-mold" refers to a device containing a surface comprised of a plurality of divots, wherein the divots measure between 100 and 200  $\mu\text{m}$  in diameter. The physical pattern of divots in the micro-mold can be specified by the manufacturer of the micro-mold. The micro-mold preferably comprises two main parts, i) the divoted substrate and ii) a system to house the divoted substrate and contain cells and media therein. The micro-mold is used to guide or determine the growth or reaggregation of cells placed therein.

**[0039]** As used herein, the term "mold housing" refers to the structure for holding both the divoted substrate and any liquid and cell materials added thereto.

**[0040]** As used herein, the term "housing scaffold" refers to a temporary framework that is used to support and influence the form of materials during the construction of the micro-mold.

**[0041]** As used herein, the term "sputtering" means a method of vapor deposition used for depositing a thin film coating on a substrate.

## B. Islet Cells Attached as a Multilayer

(not in accordance with the appended claims)

5 **[0042]** Disclosed herein is a method for producing viable individual islet cells or small islet cell clusters for implantation. Individual islet or small islet cell clusters isolated from non-fetal donor pancreases may be attached in a multilayer to the surface of a suitable biomaterial scaffold.

**[0043]** Individual islet cells, preferably beta cells, may be attached to the biomaterial scaffold. A combination of various islet  
10 cell types may be attached to the biomaterial scaffold. Small islet cell clusters comprised of two, three, four, five, six, seven, eight, nine, or ten cells may be attached to the biomaterial scaffold.

**[0044]** A multilayer of one to two, three, four, or five layers of islet cells may be attached to the biomaterial scaffold. The islet cells and  
15 small islet cell clusters on the biomaterial scaffold form a multilayer of cells about 10 to 50  $\mu\text{m}$  thick, most preferably about 20 to 40  $\mu\text{m}$  thick.

**[0045]** The multilayer of islet cells preferably has a substantially uniform thickness such that the cell thickness varies by no more than 1-2 cells across the surface of the biomaterial scaffold.

**[0046]** The individual islet cells and/or small islet cell clusters may be isolated directly from the pancreas of the donor adult subject and separated from intact islets. Suitable methods for dividing the islets into individual cells and/or small  
20 islet cell clusters include enzymatic digestion and metal-based dispersion (calcium depletion), or a combination thereof.

**[0047]** The biomaterial scaffold may be comprised of a material that provides for suitable individual islet cell or small islet cell cluster adherence to the scaffold. It is contemplated that various types of materials, including inorganic and organic materials, can be used as the biomaterial scaffold. Non-limiting examples of these materials include poly(or-  
25 thoesters), poly(anhydrides), poly(phosphoesters), poly(phosphazenes), and others. Other non-limiting materials include, for example, polysaccharides, polyesters (such as poly(lactic acid), poly(L-lysine), poly(glycolic acid) and poly(lactic-co-glycolic acid)), poly(lactic acid-co-lysine), poly(lactic acid-graft-lysine), polyanhydrides (such as poly(fatty acid dimer), poly(fumaric acid), poly(sebacic acid), poly(carboxyphenoxy propane), poly(carboxyphenoxy hexane), copolymers of these monomers and the like), poly(anhydride-co-imides), poly(amides), poly(ortho esters), poly(iminocar-  
30 bonates), poly(urethanes), poly(organophosphazenes), poly(phosphates), poly(ethylene vinyl acetate), and other acyl substituted cellulose acetates and derivatives thereof, poly(caprolactone), poly(carbonates), poly(amino acids), poly(acrylates), polyacetals, poly(cyanoacrylates), poly(styrenes), poly(vinyl chloride), poly(vinyl fluoride), poly(vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, copolymers, polystyrene, and blends or co-polymers thereof). In certain preferred aspects, the biomaterials include polysaccharides, alginate, hydroxypropyl cellulose (HPC), Nisopropylacrylamide (NIPA), polyethylene glycol, polyvinyl alcohol (PVA), polyethylenimine, chitosan (CS), chitin, dextran sulfate,  
35 heparin, chondroitin sulfate, gelatin, *etc.*, and their derivatives, co-polymers, and mixtures thereof. Other suitable biomaterials include those nylon, hyaluronan, polytetrafluoroethylene, polyvinyl formamide, and others described in Vats et al., Scaffolds and biomaterials for tissue engineering: a review of clinical applications, Clin. Otolaryngol. Allied Sci. 28(3): 165-72 (2003); Wang et al., An encapsulation system for the immunoisolation of pancreatic islets, Nat. Biotechnol. 15(4): 358-62 (1997); Orive et al., Cell encapsulation: promise and progress, Nat. Med. 9(1): 104-7 (2003).

**[0048]** Preferably, the biomaterial scaffold is comprised of a biodegradable material. Suitable biodegradable biomaterials include poly(DL-lactide-co-glycolide) (PLG), polylactic acid (PLA), or poly(lactic-co-glycolic acid) (PLGA). PLG is a well-studied polymer for drug delivery and is FDA-approved for a number of *in vivo* applications. See Berkland et al., Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions, J. Control. Release May 18, 73(1):59-74 (2001).  
40

**[0049]** The biomaterial scaffold may be coated in whole or in part with a coating that increases the islet and beta cell adhesion. Exemplary coatings include fibronectin, polyethylene glycol acetate, laminin, polyvinyl alcohol (PVA), polyethylene-alt-maleic acid (PEMA), and chitosan (CS).

**[0050]** The scaffold may also have one or more islet cell adhesion molecules ("CAMs") attached thereto to facilitate individual cell attachment and/or small islet cell cluster attachment to the scaffold. In other applications, CAMs have  
50 been previously shown to facilitate cell attachment to polymer for tissue engineering (Dunehoo et al., Cell adhesion molecules for targeted drug delivery, J. Pharm. Sci. 95: 1856-1872 (2006)). Cell adhesion molecules (CAMs) include, but are not limited to integrins (e.g.,  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ , LFA-1, VLA-4), cadherins (e.g., E-, P-, and N-cadherins), selectins (e.g., E-, L-, and P-selectins), the immunoglobulin superfamily (e.g., ICAM-1, 1CAM-2, VCAM-1, and MadCAM-1), extracellular matrix proteins (e.g., fibronectin, vitronectin, fibrinogen, collagen, laminin, and von Willebrand factor), linear and cyclic cell adhesion peptides and peptidomimetics that are derived from RGD peptides, ICAM-1 peptides, VCAM-1 peptides, cadherin peptides, and LFA-1 peptides. CAMs are essential molecules for tissue regeneration, cell morphology, locomotion, mitosis, cytokinesis, phagocytosis, and the maintenance of cell polarity. CAMs are glycoproteins found on the cell surface that act as receptors for cell-to-cell and cell-to-extracellular matrix (ECM) adhesion. It has been shown  
55

previously that cell adhesion molecules such as RGD peptides can help the process of tissue engineering, tissue regeneration, wound healing, reconstructive surgery, neural regeneration, bone grafts, and organ transplantation. In addition, E-cadherin has been shown to be important in  $\beta$ -cell adhesion (Hauge-Evans et al., Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced  $\text{Ca}^{2+}$  and insulin secretory responses of MINE pseudoislets, Diabetes, 48: 1402-1408 (1999)). In one aspect, the cell adhesion molecules are anchored onto the polymer using a covalent bond(s) including but not limited to a peptide, thioether, disulfide, or ester bond. A spacer molecule may be added between the cell adhesion molecule and the polymer to allow free interactions between the adhesion molecules on the polymer and the cell adhesion receptors on the cell surface. Studies to attached different cells to polymer studded with RGD peptide have shown the optimal spacer between polymer and the RGD peptide is around 11-46 angstroms for the optimal recognition of the RGD peptides by the cell surface receptors. The spacer can be made from but is not limited to poly ethylene glycols (PEGs), poly amino acids (e.g., poly-Gly, poly-Lys, poly-Ala), poly amino caproic acids (poly-Aca), and combinations of two or three amino acid repeats (e.g., poly-Aca-Gly). In addition to covalent linkage, the cell adhesion molecules can be adsorbed by first attaching the cell adhesion molecule that can be adsorbed into the polymer network of the patch (e.g. electrostatically, hydrophobically, or by other non-covalent interactions) onto the polymers prior to attaching the islet cells.

**[0051]** The biomaterial scaffold may have a shape that facilitates attachment of the individual islet cells or small islet cell clusters to its surface. The scaffold typically has a substantially planar surface, such as that on a patch or disk.

**[0052]** Preferably, the biomaterial scaffold comprises a substantially planar flexible patch material.

**[0053]** The biomaterial scaffold has a size suitable for attachment of individual islet cells or small islet cell clusters. For example, in one aspect, the planar patch typically has dimensions on the order of about 0.2 to 3 centimeters. The thickness of the patch is typically on the order of about 50  $\mu\text{m}$  to 1 centimeter.

**[0054]** The biomaterial scaffold may controllably release one or more growth factors, immunosuppressant agents, antibiotics, antioxidants, anti-cytokines, anti-endotoxins, T-cell adhesion blockers, angiogenesis factors, nutrients, or combinations thereof.

**[0055]** Exemplary growth factors include, epiregulin, epidermal growth factor ("EGF"), endothelial cell growth factor ("ECGF"), fibroblast growth factor ("FGF"), nerve growth factor ("NGF"), leukemia inhibitory factor ("LIF"), and bone morphogenetic protein-4 ("BMP-4"), hepatocyte growth factor ("HGF"), vascular endothelial growth factor-A ("VEGF-A"), cholecystokinin octapeptide, insulin-like growth factor, and even insulin itself. See *generally* Miao et al., In vitro and in vivo improvement of islet survival following treatment with nerve growth factor, Transplantation Feb 27;81(4):519-24 (2006); Ta et al., The defined combination of growth factors controls generation of long-term replicating islet progenitor-like cells from cultures of adult mouse pancreas, Stem Cells, Mar 23 (2006); Johannson, Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats, Endocrinology May; 147(5):23 15-24 (2006), Epub Jan 26 (2006); Kuntz et al., Effect of epiregulin on pancreatic beta cell growth and insulin secretion, Growth Factors Dec 23(4):285-93 (2005); Vasadava, Growth factors and beta cell replication, Int. J. Biochem. Cell Biol. 38(5-6):931-50 (2006), Epub Aug 31 Review (2005); Kuntz et al., Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats, JOP, Nov 10;5(6):464-75 (2004).

**[0056]** Exemplary immunosuppressant agents are well known and may be steroidal or non-steroidal. A preferred steroidal agent is prednisone. Preferred non-steroidal agents include those in the so-called Edmonton Protocol: sirolimus (Rapamune, Wyeth-Ayerst Canada), tacrolimus (Prograf, Fujisawa Canada), and anti-IL2R daclizumab (Zenapax, Roche Canada). Other immunosuppressant agents include 15-deoxyspergualin, cyclosporine, rapamycin, Rapamune (sirolimus/rapamycin), FK506, or Lisofylline (LSF).

**[0057]** Exemplary antibiotics include but are not limited to amoxicillin, penicillin, sulfa drugs, erythromycin, streptomycin, tetracycline, clarithromycin, ciprofloxacin, terconazole, azithromycin, and the like.

**[0058]** Various antioxidants are known to those skilled in the art. Particularly preferred are molecules including thiol groups such as reduced glutathione (GSH) or its precursors, glutathione or glutathione analogs, glutathione monoester, and N-acetylcysteine. Other suitable anti-oxidants include superoxide dismutase, catalase, vitamin E, Trolox, lipoic acid, lazaroids, butylated hydroxyanisole (BHA), vitamin K, and the like. Glutathione, for example, may be used in a concentration range of from about 2 to about 10 mM. See, e.g., U.S. Pat. Nos. 5,710,172; 5,696,109; and 5,670,545.

**[0059]** Suitable anti-cytokines are well known in the art and include dimethylthiourea (about 10 mM), citiolone (about 5 mM), pravastatin sodium (PRAVACHOL, about 20 mg/kg), L-NG-monomethylarginine (L-NMMA, 2 mM), lactoferrin (about 100  $\mu\text{g/ml}$ ), 4-methylprednisolone (about 20  $\mu\text{g/ml}$ ), and the like.

**[0060]** Anti-endotoxins are also known in the art and include L-NG<sup>G</sup>-monomethylarginine (L-NMMA, about 2 mM), lactoferrin (about 100  $\mu\text{g/ml}$ ), N-acetylcysteine (NAC, about 1 mM), adenosine receptor antagonists such as bamiphylline (theophylline), and anti-lipopolysaccharide compounds such as echinomycin (about 10 nM), and the like.

**[0061]** A T-cell adhesion blocker may be provided to the implanted biopolymers containing islet cells to suppress immune reaction. Addition of these blockers prevents rejection of islet transplantation. T-cell adhesion blockers have been shown to suppress T-cell activation and immune response in organ transplantation and autoimmune diseases (see Yusuf-Makagiansar et al., inhibition of LFA-1/ICAM-1 and VLA-

4/VCAM-I as a therapeutic approach to inflammation and autoimmune diseases, Medicinal Chemistry Reviews 22, 146-167 (2002); Anderson and Siahaan, Targeting 1CAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors, Peptides 24, 487-501 (2003)). The T-cell adhesion blockers include but are not limited to (a) monoclonal antibodies to ICAM-1, LFA-1, B7, CD28, CD2, and VLA-4, (b) soluble protein and its fragments such as ICAM-1, VCAM-1, MadCAM-1, (c) RGD peptides and peptidomimetics, (d) VCAM-1 peptides and peptidomimetics, (e) ICAM-1 peptides and peptidomimetics, and (f) LFA-1 peptides and peptidomimetics. In addition, peptides (e.g. GAD<sub>208-217</sub>) derived from glutamic acid decarboxylase 65 (GAD65) and the GAD bifunctional peptide inhibitor (GAD-BPI) have been shown to induce immunotolerance and suppress islet infiltration by T-cells (insulinitis). GAD<sub>208-217</sub> has been shown to block the activation of T-cells that attack the beta cells in non-obese diabetic (NOD) mice by modulating the TCR-MHC-Ag complex formation (Signal-1) during T-cell:APC interaction (Tisch et al., Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice, Diabetes 47: 894-899 (1998)). The preferred GAD-BPI comprises GAD<sub>208-217</sub> linked to a portion of the LFA-1 peptide (sequence EIAPVFLLE-[Ac-G-Ac-G-Ac]-ITDGEATDSG), and has been shown to block T-cell activation and insulinitis in NOD mice as set forth in Murray et al., Published U.S. Patent No. 2005/0107585 entitled "Signal-1/signal-2 bifunctional peptide inhibitors,".

**[0062]** Thus, these molecules may be co-administered to prevent rejection of the islet transplant. These molecules may also be delivered via controlled release mechanisms to prevent rejection of the islet transplant. Thus, the molecules may be trapped inside the biomaterial scaffold before the beta cells are attached to the scaffold.

**[0063]** The controlled release of such agents may be performed by using the protocols set forth in Raman et al., Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution, J. Control. Release. Mar 2;103(1):149-58 (2005); Berkland et al., Precise control of PLG microsphere size provides enhanced control of drug release rate, J. Control. Release. Jul 18;82(1):137-47 (2002); Schwendeman, Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems, Crit. Rev. Ther. Drug Carrier Syst. 19(1):73-98 (2002); Sershen et al., Implantable, polymeric systems for modulated drug delivery, Adv. Drug Deliv. Rev. 5;54(9):1225-1235 (2002).

#### C. Production of Islets on Divoted Micro-Molds

**[0064]** The present invention enables a method for *in vitro* production of viable small islets. In one aspect, dispersed islet cells isolated from non-fetal donor pancreases are placed in groups into individual divots of a micro-mold and cultured to form reaggregated islets whose shape and size are influenced by divot dimensions.

**[0065]** The divots of the micro-mold have a size suitable for formation of small islets. For example, in one aspect, the micro-mold typically has dimensions on the order of about 30-35mm in diameter, but this size is not limited by production methods and could be ramped up to 30 x 30 cm. The divots typically have dimensions on the order of 100-200  $\mu\text{m}$  ( $\pm 20\%$ ) in diameter and 60-100 ( $\pm 20\%$ )  $\mu\text{m}$  in depth. Preferably, for the production of islets the divots are 100  $\mu\text{m}$  ( $\pm 20\%$ ) in diameter and 60  $\mu\text{m}$  ( $\pm 20\%$ ) in depth.

**[0066]** In another aspect, the micro-mold can be used to generate populations of optimally shaped and sized islets suitable for transplantation or *in vitro* study. For example, in one aspect, the population of islets generated in micro-molds has a mean diameter of 50  $\mu\text{m}$  or less. In other aspects, the population is characterized by at least 85% viable cells, preferably greater than 90% or 95% viable cells, more preferably the population is characterized by greater than 99% viable cells.

**[0067]** In yet another aspect, the population of islets generated in micro-molds can be characterized by high levels of insulin secretion. For example, small islets reaggregated in micro-molds are characterized by greater levels of insulin secretion relative to native small islets, preferably greater than 20 times more insulin secretion, more preferably greater than 100 times more insulin secretion. For example, the reaggregated islets measured secretion of approximately 10ng/IE, shown in Figure 23. This is 41 times greater than the best calculated value from Crim et al., 2010. One difficulty in comparing insulin secretion data between laboratories is that many investigators fail to report their insulin secretion per islet volume. In the case of Crim et al, they reported insulin secretion per 50 islets, but did not indicate the average size of the islets. Thus, one can only assume that their 50 islets were each equivalent to the previously defined islet volume of 1 islet equivalency (IE). Our laboratory always reports insulin secretion normalized for the total volume of islets and cells by dividing by the IE. With the assumption made for the Crim paper, the reaggregated islets described herein release over 40 times more insulin in response to high glucose than the best conditions reported by Crim et al.

**[0068]** In one embodiment of the present invention, the micro-mold will be used to create cells useful for *in vitro* testing and other *in vitro* applications. In that embodiment, the micro-mold surface is preferably made of glass with the mold sides (the housing system) made of PDMS.

**[0069]** In another embodiment, the micro-mold is created to be implantable and would be made of bio-compatible material. In that embodiment, preferable materials are any number of biopolymers described previously.

**[0070]** In another aspect, the micro-mold divots are designed to provide optimal physical reformation conditions for

non-islet cells. It is contemplated that various types of cells can be formed in the divots of the present invention. Non-limiting examples include long neuronal pathways, glomerular-like filters, vessels, replacement alveoli, etc. Aggregation of stem cells or reprogrammed cells in a small, well-defined shape, such as the micro-mold, would also be an appropriate use of this invention. Preferable cell types include those in which a 3-D structure is important to cell function.

5 [0071] In general, FIG. 24 is a schematic showing the method of the present invention. Native large islet clusters, taken from a pancreas or other islet source, are disbursed into single islet cells and loaded onto a micro-mold with divots. By "dispersed cells" we mean that the majority (typically at least 90%) of cells are single cells, with a lesser proportion of cells bound together as doublets or triplets. The dispersed cells are placed into the micro-mold in a manner that leads to groups of the dispersed cells settling into each divot. Preferably, 30-150 cells settle into each divot.

10 [0072] Example 5 discloses a preferred method of dispersing islets into single cells and incubation of the cells in micro-molds. Preferably, the dissociation is in a media blend formulated in the KU Diabetes Research Laboratory. This blend includes nine parts calcium-magnesium free Hank's Balanced Salt Solution and one part papain (50 units/ml). In contrast, most islet dissociation is accomplished using trypsin or enzymes other than papain. The dissociation is carried out at 37°C, with rotation. Finally the islets are dispersed into single cells by manually pipetting them and observing with a hemocytometer until at least 90% of the cells are separated into single cells. Example 5 also discloses preferable conditions for the reaggregation of the islet cells within the micro-molds. In general, the cells remain as single cells or loosely attached groups of cells through day two as noted in FIG. 14. However, by day five or six those same cells in the divot have reorganized into a 3D structure that is often spherical (for examples see FIG 18-19A and 21). Typically by day five the reaggregated islets can withstand removal from the molds and function as independent islets.

20 [0073] During this period of time, the cells take on the three-dimensional shape of a native islet. The mean diameter of the islets formed in the divots is less than 50  $\mu\text{m}$ . Example 5 describes the morphological nature of the small islets formed in the micro-molds.

[0074] In one embodiment of the present invention, cells dispersed in low concentration can be added to the micro-mold, such that as few as two or three cells fall in each divot, and such that cells within divots are capable of growth and division. The shape and size of the cell mass grown in a divot in this manner would be influenced by the physical dimensions of the divot. Preferably, micro-molds are loaded with islet cells, concentrated such that as few as two or three islet cells will occupy each divot, wherein islet cells will grow and aggregate together to form small islets, preferably 30-40  $\mu\text{m}$  in diameter.

30 [0075] In another embodiment of the present invention, one may wish to incorporate chemicals or biological molecules into the engineered islets at the time of reaggregation. These molecules include growth factors, cytokines, chemokines, DMARDs (disease-modifying antirheumatic drugs), anti-inflammatories, and antibiotics. Molecules or miniature devices to increase oxygen tension at the transplant site could be incorporated into the reaggregated islets, especially if an implantable micro-mold substrate were used. Other non-limiting classes of molecules that could be added at the time of reaggregation includes drugs to induce insulin release, small molecules, peptides, proteins, antibodies (e.g. against CD11a, CD11b, CD11c, CD18), and nucleic acids (e.g. DNA or RNA).

35 [0076] Such molecules could typically be incorporated into the islets at the time of loading into the micro-molds. The molecules would be added to the media with the dispersed cells so that they would be either taken up by the cells or adhere to the cells during aggregation. Alternatively, the cells could be modified prior to reaggregation via standard transfection methods that would result in increased or decreased production of the user's target protein. After the formation of the reaggregates, the newly-formed islets could be encapsulated with biopolymers that would carry chemicals such as immunosuppressors or other molecules of interest such as growth factors. Alternatively, with implantable micro-molds, the molds could be impregnated with the molecule of choice.

40 [0077] The method of the present invention can be designed to form cell aggregates for subsequent transplantation or for drug or device testing. Example 5 describes preferable methods for reaggregating cells for transplant and drug screening and preferable methods for doing so.

[0078] In another aspect, the present invention enables a method for high-throughput screening of drugs, chemicals, or other small molecules. It is contemplated that the pattern and dimensions of divots in the present micro-mold can be designed to accommodate individual interventions in each divot.

45 [0079] In another aspect, the divoted micro-molds are generated from a biopolymer suitable for transplantation into an animal host.

[0080] For *in vitro* work, a non-adherent substrate surface, such as glass, is preferable.

[0081] Adherence of the cells to the biopolymers has been tested and is described in Table 1 and FIG. 8.

55 **EXAMPLE 1: Size of Islet Impacts Viability and Transplantation Success** (not in accordance with the appended claims)

[0082] This example investigated how islet size affected transplantation success in rats. In this example, techniques for isolating islets are described, and cell viability was measured. Both large islets (greater

than 125  $\mu\text{m}$ ) and small islets (less than 125  $\mu\text{m}$ ) were transplanted in order to assess the effect of islet size on transplantation success. As discussed below, small rat islets are superior to large islets in *in vitro* function and in *in vivo* transplantation outcomes. These experiments are also described in MacGregor et al., Small rat islets are superior to large islets in *in vitro* function and in transplantation outcomes, Am. J. Physiol. Endocrinol. Metab. May;290(5):E771-9 (2006).

### Rat Islet Isolation.

**[0083]** To isolate large and small islets, adult male DA rats were anesthetized by intraperitoneal injection of a mixture of ketamine and xylazine. The peritoneal cavity was exposed and the pancreatic ductal connection to the intestine clamped. The pancreas was cannulated *in situ* via the common bile duct, and distended by pumping a cold solution of collagenase into the duct. Collagenase (CLS-1, Worthington Biochemical Corp, Lakewood, NJ) was dissolved in 20 ml of Leibovitz L15 at 450 U/ml. Subsequently the distended pancreas was excised, transferred to 50 ml centrifuge tubes, and incubated for about 20-30 minutes with gentle tumbling in a 37 °C incubator. Following incubation, the tube was gently shaken to dislodge islets. The contents of the tube were placed in diluted ice-cold Hank's Balanced Salt Solution ("HBSS") containing 10% of newborn calf serum. The digest was allowed to settle at 1 x g and the supernatant removed. More HBSS/serum was added and the process repeated. The washed digest was passed through a 500 micron stainless steel screen and sedimented about 1 minute at 300 x g in a refrigerated centrifuge. The pellet was mixed with 10 mL of 1.110 gm/mL Histopaque (density = 1.1085, Sigma Diagnostics Inc., St. Louis, Missouri) and centrifuged 10 minutes at 800 x g. The islets floating on the gradient were collected and sedimented separately, then placed into Ham's F12 culture medium containing 10% of fetal bovine serum and put into a 37 °C culture chamber containing 5% CO<sub>2</sub>.

### Yield

**[0084]** For yield measurements, triplicate samples of each batch of islets were examined, each comprising approximately 2% of the islet fraction. Individual islets were counted and their diameters measured. For irregular-shaped islets, 3 to 4 diameter measurements were taken at different locations on the islet and the average used. Islet volumes were calculated and converted to islet equivalents for the sample and the entire islet fraction. Small islets were defined as those having a diameter of less than about 125  $\mu\text{m}$  compared to large islet with a diameter of about 125  $\mu\text{m}$  or greater.

**[0085]** To separate small islets from large islets, fresh islets or islets cultured overnight were sedimented and then placed in 1-2 ml of L15 medium. The islets were then quickly layered over a single-step gradient of 5% BSA in L15. Sedimentation at 1 x g was permitted to occur for an empirically set period of time until large islets were observed in the bottom of the tube. At that point the top two milliliters (without BSA) of the gradient was discarded, and all but the bottom 2 ml was carefully removed to define the small islet population. The sedimented islets and those in the bottom 2 milliliters were combined as the large islet fraction. Gradients were repeated if needed to optimize the separation of large and small islets. Final islet fractions were sedimented and placed into culture in a 1:1 mixture of Ham's F12 and glucose-free RPMI 1640 (glucose = 5 mM) until glucose sensitivity experiments were performed.

### Viability

**[0086]** To test viability, islets were placed in a 500  $\mu\text{l}$  volume of L-15 media with live/dead fluorophores, Sytox (Molecular Probes, 1  $\mu\text{M}$ ) and Calcein (Molecular Probes, 0.5  $\mu\text{M}$ ), and incubated for about 15 to 30 minutes at 37 °C. Islets were rinsed with phosphate buffered saline (PBS) consisting of (in mM): 137 NaCl, 2.7 KCl, 4.3 Na<sub>2</sub>HPO<sub>4</sub> and 1.4 KH<sub>2</sub>PO<sub>4</sub>, pH 7.4 and placed in the Attofluor Chamber (Molecular Probes) on the Olympus Fluoview 300 confocal microscope housed in the Diabetes Research Laboratory. Images were acquired using 40X or 60X objectives. All images were collected within 20 minutes of removal of the islets from the media. Three simultaneous images were collected for each islet using He:Ne and Argon lasers and a third bright-field image.

**[0087]** As shown in FIG. 2, large intact islets (greater than 125  $\mu\text{m}$ ), whether human or rat, maintained in culture typically exhibit a significant percentage of necrotic (12.6%) and apoptotic (6.3 %) cells after only four days with cell death increasing over time. Smaller islets (less than 125  $\mu\text{m}$ ) exhibited extended viability, but still showed precipitous cell death at later time points (beyond one week). The viability of these small islets was followed for up to one week and it was found that they maintain high viability percentages from 99 to 86%. This is in comparison to intact large islets, which have viability levels that fall to below 50% after several days in culture. As shown in FIG. 2, individually dispersed islet cells maintain a high viability profile in culture similar to the small intact islets.

**[0088]** Live/dead analysis was completed by identifying the islets in the field and encircling the regions of interest. Background fluorescence was subtracted from all images. Viability percentages were calculated by developing hue histograms using Photoshop (Adobe) from the fields of interest and calculating the total pixels in the green hue (live) and red (dead). The ratio representing the live cells divided by the total islet area was calculated as the percent live

value. Islet diameters and perimeters were calculated using Scion software so that viability values could be categorized according to the size of the islet.

### Transplant Studies

**[0089]** The effect of islet size on transplantation success was also investigated. In the experiments, diabetes was induced in the recipient animals by injecting streptozotocin (65mg/kg) intraperitoneally (1 injection). When blood glucose levels are greater than 250 mg/dl for three consecutive days, the rats were considered diabetic.

**[0090]** Rats were anesthetized with pentobarbital 45 mg/kg. After the rat was shaved and cleaned with betadine scrub, an incision was made in the body wall on the left flank. The kidney was delivered into the wound, and a small incision was made in the kidney capsule. The large or small islets were placed under the capsule using a small bore pipette. The kidney was placed back into original position and the incision closed with wound clips. Beef/porcine zinc- insulin (NPI-1 Iletin I) injections (2 times/day) were given to recipients for three days post-islet transplant to reduce the stress of hyperglycemia on the newly transplanted islets.

**[0091]** Transplantations of the large or small rat islets were completed (n=10 transplantations/group). The streptozotocin-induced diabetic DA rats received a marginal mass (1000IE) of either large (greater than 150  $\mu$ m) or small (less than 125  $\mu$ m) syngeneic islets under the kidney capsule. Blood glucose levels were monitored for eight weeks. FIGS. 3(A) and 3(B) show the results from the first five transplants for each group. All of the recipients of large islets remained hyperglycemic after transplantation (10 of 10). In contrast, 8 of 10 recipients of small islets had blood glucose levels close to or at normal levels 7-10 days after transplantation, which remained normal for the entire eight-week period.

**[0092]** Islet grafts from the kidney capsule were removed eight weeks after transplantation. The tissue was fixed and immunolabeled for insulin. FIG. 4 (left panel) shows the graft from an animal that received small islet transplantation and was euglycemic for the eight weeks. There was substantial staining for insulin in the graft. In contrast, FIG. 4 (right panel) the animal that received the transplantation of large islets continued to be hyperglycemic for the eight week period and showed little immunolabeling for insulin in the grafts.

**[0093]** Together, the foregoing experiments show that smaller islets (less than 125  $\mu$ m) were superior to large islets (more than 125  $\mu$ m) in viability, *in vivo* functional assays, and in transplant outcomes. In addition, an average pancreas yielded about three times more small islets than large islets, and the smaller islets were approximately 20% more viable. Most importantly, the small islets were far superior to large islets when transplanted into diabetic animals.

### **EXAMPLE 2: Conversion of Large Islets Into Individual Islet Cells or Small Islet Cell Clusters** (not in accordance with the appended claims)

**[0094]** This example illustrates methods for fragmenting or dispersing intact islets into small islet cell clusters (such as the cluster shown in FIG. 5) and individual islet cells. The small islet cell cluster in FIG. 6(A) was created using a conventional enzymatic digestion, while the small islet cell cluster in FIG. 6(B) was formed with graded calcium depletion. As the image in FIG. 6(A) illustrates, enzymatic dispersion breaks the islet down into small islet cell clusters, but it does not "open" the cluster up so the cells on the interior of the cluster have a diffusional barrier that is several cells thick. In contrast, for small islet cell clusters formed using calcium depletion (FIG. 6(B)), the cluster has an "open" morphology such that there is a smaller diffusional barrier for each cell of the when the small islet cell cluster. It is anticipated that a combination of enzymatic digestion and calcium depletion may also be used to convert intact islets into small islet cell clusters, which is shown in FIG. 6(C).

#### **a. Enzyme Digestion**

**[0095]** Different enzyme cocktails can be used to fragment intact islets into small islet cell clusters and individual islet cells. Exemplary enzymatic digestion methods are disclosed in U.S. Patent No. 6,783,954 In this example, twelve enzyme cocktails were used with varying degrees of success, including one cocktail which included papain.

**[0096]** To isolate pancreatic islets, Sprague-Dawley rats were anesthetized by an intraperitoneal injection of ketamine and xylazine. The peritoneal cavity was exposed and the pancreatic ductal connection to the intestine clamped. The pancreas was cannulated *in situ* via the common bile duct, and distended by pumping a cold solution of collagenase into the duct. Subsequently, the distended pancreas was excised, transferred to centrifuge tubes, and incubated for about 30 minutes with gentle tumbling in a 37 °C. The washed digest was passed through a screen and sedimented in a refrigerated centrifuge. The pellet was mixed with Histopaque (density = 1.1085, Sigma Diagnostics Inc., St. Louis, MO) and centrifuged. The islets were then placed into Ham's F12 culture medium containing 10% of fetal bovine serum and put into a 37 °C culture chamber containing 5% CO<sub>2</sub>.

**[0097]** The standard protocol for beta cell isolation included incubating intact islets (isolation using techniques described herein) in Hanks Balanced Salt Solution ("HBSS") with 4.8 mM Hepes. See Balamurugan et al., Flexible management

of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata. *Am. J. Transplant* 3(9): 113542 (2003). For enzymatic digestion, a final 9 ml of Hanks balanced salt solution containing 1 ml of papain (50 units/ml) was added to the islets. Islets were initially pipetted up and down gently to ensure complete rinsing. Islets were allowed to settle to the bottom of the tube and most of the supernatant was removed. Islets in the enzyme were rotated slowly (about 10 rpm) for about 30 minutes at 37 °C. At this point, small islet clusters were formed with some single dispersed cells, and removed from the solution. Typically, the cells were transferred to CMRL 1066 or Memphis SMF as the final culture media.

**[0098]** Cells were stained with dithizone to identify the beta cells within the clusters as generally shown in FIGS. 5 and 6(A) (enzyme).

### b. Metal-Based Fragmentation

**[0099]** Intact islets may also be fragmented into small islet cell clusters and individual islet cells using a metal-based fragmentation approach. The interesting finding of metal-based fragmentation is that the resulting small islet cell clusters are less-compact or have an "open" morphology. Cell adhesion molecules, such as E-cadherin, hold the islet together, but require divalent metals to function. See Hauge-Evans et al., *Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced Ca<sup>2+</sup> and insulin secretory responses of MIN6 pseudoislets*, *Diabetes* 48(7): 1402-8 (1999). Thus, culturing islets in calcium-free media for about one hour results in a "loosening" and fracturing of the islet structure (see FIG. 6(B)) in comparison to utilizing enzymes alone, which yields a denser islet structure (see FIG. 6(A)). Further, after "loosening" the islets using calcium depletion, the remaining clumps of beta cells are more easily dispersed by traditional enzymes (see FIG. 6(C)).

**[0100]** The details of the metal-based fragmentation are as follows. To obtain individual islet cells and small islet cell clusters, the islets were in calcium-magnesium free Hanks Balanced Salt Solution + 4.8mM Hepes. After incubation at about 37 °C for about 30 minutes, the cells were pipetted, dispersing them into small islet cell clusters or single cells. The cells were transferred to CMRL 1066 as the final culture media. When necessary, the small islet cell clusters or beta cells were identified with dithizone. See Myhill et al., *Culture prior to transplantation preserves the ultrastructural integrity of monkey pancreatic islets*, *J. Electron Microsc. (Tokyo)* 52(4): 399-405 (2003).

**[0101]** As shown in FIG. 6(B), the small islet cell clusters derived by calcium depletion alone had an irregular tubular arrangement, which may be optimal for perfusion of the core of the cluster. In addition, the clusters derived from metal-based dispersion take only about one hour to produce, while the enzyme approach to fragmentation can take up to 48 hours.

### c. Combination of Enzymatic Digestion and Metal Dispersion

**[0102]** Experiments were also performed using a combination of enzymatic digestion and metal depletion as a dispersion technique. Intact islets were rinsed with 9 ml of Hank's balanced salt solution (without calcium or magnesium) with 4.8 mM Hepes. Islets were initially pipetted up and down gently to ensure complete rinsing. Islets were allowed to settle to the bottom of the tube and most of the supernatant was removed. The islets could be repeatedly washed to remove all calcium and magnesium.

**[0103]** A final 9 ml of calcium and magnesium-free Hank's balanced salt solution containing 1 ml of papain (50 units/ml) was added to the islets. Islets in the enzyme were rotated slowly (10 rpm) for 30 minutes. At this point small islet clusters could be removed from the solution. Strong pipetting 2-3 times at a moderate speed resulted in single cells.

**[0104]** Cells were centrifuged for 5 minutes at 1500 rcf, 25 °C. Single cells were resuspended using the appropriate culture media (depending on the subsequent assays). Cells were stored in an incubator at 37 °C and 5% CO<sub>2</sub>. As shown in FIG. 6(C), combination of the enzyme and calcium depletion method results in a small islet cell clusters or single cells. Moreover, the combination was an overall faster dispersion protocol, but caution must be used to avoid over-digested and damaged cells.

**[0105]** In these experiments, YO-PRO-1 and propidium iodide (Vibrant Apoptotic Assays, Molecular Probes) were used to determine necrotic and apoptotic cells. For the assay, cells were placed with PBS in the Attolfluor Chamber (Molecular Probes) on the Olympus Fluoview 300 laser confocal microscope. All images were collected within 20 minutes of removal of the cells from the media. Three simultaneous images were collected for each islet using He:Ne and Argon lasers and a third bright-field image. Live/dead analysis was completed by identifying the cells in the field using transmitted light. Green cells indicate apoptosis, while yellow/red indicates necrotic cell death. Cells lacking fluorescence emission were live. The fluorescence images were overlaid with the transmitted-light image (gray).

**EXAMPLE 3: Preparation of Individual Islet Cells and Small Islet Clusters onto a Patch Biomaterial Scaffold** (not in accordance with the appended claims)

[0106] The foregoing examples indicate that small islet cell clusters and even individual beta cells should represent the highest achievable free surface area for transporting oxygen, glucose, etc. Thus, in this example, individual islet cells or small islet cell clusters were templated onto a biomaterial scaffold material, such as a patch as generally shown in FIG. 7, to form a multilayer of islet cells.

### Screening of Scaffold Materials

[0107] In this example, optimization of various biomaterials useful for preparing the scaffolds were investigated by measuring the relative adhesion of the islet cells to the biomaterial. It is preferable that the scaffold material be easy to handle without dissociating the tissue and biomaterial backing to enable facile implantation. Table 1 illustrates a wide variety of biomaterials which were selected for interactions with beta cells. Several of these materials possess a history of use as implants.

[0108] In a typical experiment, 1% stock solutions of the listed biomaterials first were prepared. Most materials dissolved in deionized water at neutral pH. Chitosan required a lower pH of about 5.5 to dissolve (hydrochloric acid was used) and other materials required organic solvents; for example Cellform™ in ethanol and poly(DL-lactic-co-glycolic) acid (PLGA) in dichloromethane. Polymers normally soluble in water (e.g. dextran sulfate, alginate, etc.) can be cross-linked to form the film matrix. Approximately 25 μL of each stock solution was added to three individual wells in 96-well plates and left to evaporate or vacuum dried, thus, depositing a thin biomaterial film at the bottom of each well. Residual solvent content is miniscule and did not induce toxicity in cells. Several proteins offered commercially to promote cell adhesion on well plates (e.g. fibronectin, laminin, etc.) were prescreened for cell adhesion as well.

[0109] A dilute suspension of beta cells was incubated in the 96-well plates overnight and washed three times to remove unbound beta cells. The beta cell suspension was homogeneous and equal aliquots per well were assumed to contain a similar quantity of beta cells. All cell counts were normalized to cell counts from wells that did not include a biomaterial film. In general, mildly hydrophobic polymers performed well for adhering beta cells (Table 1).

**Table 1: Relative beta cell adhesion of selected biomaterials**

Biomaterial		Relative cell adhesion
Empty well (control)		1
50:50 PLGA carboxyl	Mw = 5.5 kDa	9.8 ± 0.9
Laminin		8.7 ± 0.6
Dextran Sulfate	Mw = 500 kDa	7.4 ± 3.0
50:50 PLGA-methylester	iv = 0.31dL/g	6.8 ± 0.7
Polyvinylpyrrolidone		5.8 ± 1.2
Dextran Sulfate	MW= 8 kDa	5.4 ± 1.0
50:50 PLGA-methylester	iv = 0.9 dL/g	5.2 ± 0.8
50:50 PLGA-methylester	iv = 0.58 dL/g	4.4 ± 0.7
Pluronic		4.0 ± 1.5
50:50 PLGA-carboxyl	iv = 0.12 dL/g	3.9 ± 0.7
Polyethylenimine	Mw = 25 kDa	3.8 ± 0.2
Fibronectin		3.7 ± 0.7
PEG acrylate		3.1 ± 0.5
Chitosan	Mw = 15 kDa	3.1 ± 0.1
Collagen IV		2.9 ± 1.4
PEG	Mw = 8 kDa	2.8 ± 1.1
Alginate		2.4 ± 1.2
Gelatin		2.0 ± 0.2

(continued)

Biomaterial		Relative cell adhesion
Heparin		1.7 ± 0.2
Cellform™		1.7 ± 0.7
Chitosan	Mw = 100 kDa	1.5 ± 0.7
Polyethylenimine	Mw = 800 Da	1.2 ± 1.0
Polyvinylpyrrolidone		n.d.
Poly(vinyl alcohol)		n.d.
Poly(acrylic acid)		n.d.
iv = inherent viscosity		

**[0110]** Cell adhesion was determined by counting the number of attached cells 24 hours after plating on the biomaterial and following three washes. The counts were normalized to the number of cells that attach to a well bottom lacking a biomaterial (see empty well, control) using the following calculation: number of cells attached in the well of interest/number of cells in empty well. Each experiment was repeated in triplicate.

**[0111]** In general, mildly hydrophobic polymers performed well for adhering beta cells. Optical micrographs indicated that cell morphology was also affected by the biomaterial. Beta cells on chitosan (MW = 100 kDa) exhibited a smooth, rounded surface while beta cells on laminin demonstrated a spread and ruffled morphology (see FIG. 8). Fluorescent staining of actin in beta cells on the laminin substrate revealed strongly fluorescent cytoskeleton focal points suggesting firm cell adhesion.

#### Preparation of Islet Cell Patch

**[0112]** In this example, the islet cells were bound to a biomaterial scaffold patch comprising PLGA. In vascularized islets of Langerhans, the average beta cell is no more than about 25 μm away from a blood vessel. See Wayland, Microcirculation in pancreatic function, *Microsc. Res. Tech.* 37(5-6): 418-33 (1997). Because beta cells are about 10 μm in diameter, it is anticipated that cell layer thickness of about three cells would most accurately mimic the native beta cell environment.

**[0113]** In general, islets were isolated from a rat pancreas and dispersed into single cells or small cell clusters as described previously. Islet cells and small islet cell clusters in HBSS media (0.5 ml) were added to each well and allowed to culture onto the biomaterial for 3 to 4 hours. Plates with biopolymers in the wells were spun in a centrifuge at room temperature at about 3500 rpm for about 10 minutes to assist the cells in attaching to the biopolymer. Half of the media was removed from each well, replaced with media containing a fresh islet cell or small islet cell cluster suspension, and allowed to attach (either by gravity or by centrifugation). This was repeated three times. Results of these experiments are shown FIG. 9. Additional layers of islet cells can be attached to the patch of polymer following repeated washing when the centrifugation method was employed, compared to cells cultured on polymers without centrifugation. About three to five layers of cells remain consistently attached to 50:50 PLGA at 0.58dL/g (in HFIP) or 0.9 dL/g polymer with repeated media changes. To control the thickness of the beta cell layer, either the volume of cell culture added to each well and/or the number of aliquots added to each well in repeated deposition cycle can be controlled.

#### EXAMPLE 4: Prophetic Testing of islet Cells on Biomaterial Scaffold (not in accordance with the appended claims)

**[0114]** In this example, biomaterial patches having a multilayer of islet cells attached thereto will be further investigated. Viability measures and insulin production assays will be performed. In addition the device will be investigated as an implantable device for the treatment of diabetes.

**[0115]** *Viability measurements.* Apoptosis versus necrosis experiments will be completed as previously. The percentage live cells will be calculated per cross sectional area of the beta cell layers for comparison to native islets on days 0, 1, 3, 7, 14, and 30 for three samples. Data will be plotted as percent viable cells versus time and we will determine if a statistically significant difference exists between the viability trends for different numbers of beta cell layers using a t-test. In addition, recording of the percentage of cell death attributed to necrosis or apoptosis will be made.

**[0116]** *Insulin production assays.* Insulin production will be measured using static incubation (ELISA) under conditions of low glucose (3 mM), high glucose (30 mM), and high glucose/depolarization (25 mM K+) (Dean 1989). Each well in 12-well plates will be preincubated with fresh media at

37 °C and 5% CO<sub>2</sub>. For experimental measurement, the various beta cell patches will be incubated for 2 hours in fresh media containing either 3 or 30 mM glucose. One additional group of wells is incubated in 30 mM glucose, containing 25 mM KCl with appropriately reduced NaCl. Each patch type will be evaluated in triplicate for each condition tested. Media samples will be assayed for insulin content using an ELISA immunoassay. The results will be expressed as averages of the triplicate samples with standard deviation and compared using a t-test for statistical significance. MacGregor et al., Small rat islets are superior to large islets in in vitro function and in transplantation outcomes, Am. J. Physiol. Endocrinol. Metab. 290(5); E771-779 (2006).

**[0117]** *Implantation of patches and islets.* Diabetes will be induced in adult recipient Diabetes Resistant BioBreeding (DRBB) Worcester rat is a model of autoimmune diabetes that parallels type I diabetes in humans. Four-week old rats will be purchased from Biomedical Research Models, Inc, Animals will be randomly divided into 2 groups: patch recipients and islet recipients (6 per group). For the induction of diabetes the DRBB rats will be treated with a combination of anti-RT6 monoclonal antibody (DS4.23 hybridoma (kindly provided by Dr. Dale L. Greiner, University of Massachusetts Medical Center; 2 ml tissue culture medium injected 5 times/week) and non-specific immune system activator poly I:C (Sigma; 5ug/g of body weight injected 3 times/week). The injections will be given over a 3-week period. On the date of repeated hyperglycemia (blood glucose levels >250 mg/dl for 3 consecutive days), the animals will be considered diabetic and the treatment discontinued (Semis 2004). With this method, 95% of the rats become diabetic by the end of the 3rd week. Implantation of beta cell patches and islets will be done in the kidney subcapsule. DA (Dark Agouti) rats will serve as beta cell donors. Rats will be anesthetized with pentobarbital (45 mg/kg) and the kidney delivered to an incision made in the body wall on the left flank. A moderate incision will be made in the kidney capsule, and the beta cell patch placed under the capsule. A minimum of 4 patches with variable biomaterial and/or cell layer thickness will be implanted. Islet implants typically require a smaller incision and infusion through a small bore pipette. Recipient groups will receive either 1000 or 2000 IE of islets for transplants or an equivalency of beta cells on the patch substrate. Significant improvement in performance (patch type versus islets) should be detectable if the minimum necessary islets for success (1000 IE) are transplanted and compared to a higher islet volume (2000 IE). Beef/porcine zinc-insulin (NPH Iletin 1) injections (2 times/day) will be given for 3 days post-islet transplant to reduce the stress of hyperglycemia.

**[0118]** *In vivo determination of glycemia.* The blood glucose of rats will be monitored for 4 weeks to determine whether the patch or islet implants can induce euglycemia. The glycemic control of the animals will be followed by taking blood glucose measurements daily. Plasma glucose levels will be monitored by obtaining blood samples from the tail on a daily basis for the first 3 weeks, and then 2 times/week using the Freestyle glucose meter (TheraSense). Generally reversal of diabetes is achieved within 24 hours of islet transplantation, similar outcomes should be achieved with the patches.

**[0119]** *Analysis of explanted beta cell patches.* The patches or islets will be retrieved after 14 or 30 days for immunostaining (insulin and glucagon), viability measurement, and detection of apoptosis. In some cases, rats achieving euglycemia will be maintained for 8 weeks before analysis. Immunohistochemistry on the sections will be completed using antibodies for insulin and glucagon. Images will be processed using colorimetric analysis to determine the cross-sectional area positive for each of the stains. Negative control slides will be prepared and analyzed. Initially, we will use a dithizone stain to identify beta cells. DNA-fragmentation, indicative of cellular apoptosis, will be completed using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay. Patches or islets will be prepared for histology using 10% formalin embedded in paraffin as we have previously done. The TUNEL kit (In Situ Cell Death Detection Kit, Roche Diagnostics) will be used to label the histological sections. The patches and islets will be analyzed both for the number and distribution of TUNEL+ cells by a blinded researcher. Images of histological sections will be reconstructed into full 3D images of islets. In this way, apoptotic cells throughout single islets can be identified. Sections will be counterstained with hematoxylin and visualized under the light microscope. To identify the insulin-secreting cells within the islets, anti-insulin antibody will be used to label samples and detected with a rhodamine secondary antibody. We anticipate collecting a minimum of 10 islets/rat post transplantation for apoptosis analysis. Negative control slides will be prepared as necessary. In addition to TUNEL analysis, patches will be fixed for subsequent electron microscopy using the core microscopy facility. Identification of beta cell layers and of infiltrating cells will be conducted in this manner.

#### **EXAMPLE 5: Preparation of optimally sized cells using a micro-mold**

**[0120]** In this Example, an additional device for reaggregating cells was developed and designed and methods for generating a micro-mold having multiple individual divots etched into the surface of substrate are described.

**[0121]** In general, a pancreas is broken down into native large islets (greater than 150 μm) and native small islets (less than 125 μm). Large and small islets are separated, and small islets are placed in culture (in some embodiments the small islet culture will later be added back to the newly reaggated islets.) The large native islets are dispersed into single cell suspension and allowed to settle into the micro-mold. The size of the produced islet can be manipulated by the number of cells loaded into the micro-mold. Depending on the cell suspension, typically 20-100 (+/- 20%) cells will

fall into each divot to bind to each other, forming a new reaggregated small islet. The single cells in individual divots are cultured under conditions to promote formation of the 3D structure that resembles the native small islet wherein the size and shape of reaggregated islets are influenced by the size and shape of the divot. Ability to vary the number of cells in the divots by concentrating (by determining the cell density in suspension) allows us to produce a very small (under 30  $\mu\text{m}$ ) or mid-sized (50-90  $\mu\text{m}$ ) reaggregated islet. This control may turn out to be important when forming other 3D cellular structures like the mini-tumors for chemotherapy testing.

**[0122]** Unlike the biomaterial scaffold patch of Example 3 *supra*, the divoted micro-mold described in this example does not require cells to attach to the substrate surface. As discussed below, islet cells reaggregated in a micro-mold are optimally sized, viable, and cell populations derived from micro-molds are characterized by high percentage viability and high levels of insulin secretion.

#### Development of micro-mold.

**[0123]** *Divots as the physical reaggregation environment.* In an effort to reaggregate single cells into optimally sized small islets, we hypothesized that forming the islets in a physically constrained environment would guide the shape of the cell mass during reaggregation. To this end, we determined that an optimal physical reaggregation environment would be similar to both the shape and size of the desired cellular end product. The dimension range used in our first experiments (100  $\mu\text{m}$  diameter and 60  $\mu\text{m}$  depth) is optimal for production of reaggregated islets under 50  $\mu\text{m}$  in diameter (on average). The 60  $\mu\text{m}$  depth allows easy retrieval of the reaggregated islets without breaking them into smaller pieces. A rounded bottom in each reaggregation environment guided reaggregation of the cell mass into a roughly spherical shape. We refer to these physical reaggregation environments with specified dimensions including rounded bottoms as "divots". The dimensions and placement of the divots can be varied according to the needs of the user.

**[0124]** *Micro-mold design.* In an effort to generate populations of optimally sized small islets, we designed a micro-mold containing a surface comprising numerous divots. The dimensions of the divots in this micro-mold and their spatial relationship to one another within the micro-mold were specified by the user. AutoCAD software was used to create electronic templates of the micro-molds. The template delineates the size, shape and distribution of divots on the mold surface. The divoted substrate is set within a larger housing capable of containing liquids without leakage also referred to herein as the mold housing (FIG. 10). The dimensions of both the micro-mold and divots within the micro-mold can be varied according to the needs of the user. For example, if the goal were to use the molds for drug testing, a larger and or deeper divot might be tested so as to hold a larger volume of tested compound per divot. If the cells of interest were not islets, the dimensions of the divot could be specified otherwise to meet the optimal reaggregation or growth criteria for the cell type of interest.

**[0125]** *Substrate for divoted surface.* There are several physical properties that are important when choosing a substrate. Using a silicon dioxide ( $\text{SiO}_2$ ) based substance is preferable for wet etching with a buffered hydrofluoric (HF) acid solution. The HF acid etches a substrate by reacting the  $\text{SiO}_2$  molecules. In addition, for the *in vitro* use of the micro-mold, it is preferable to choose a substrate to which cells would not adhere, allowing easier removal of reaggregated islets from divots. A transparent substrate allows for viewing contents within divots under a microscope without having to transfer to another plate. A sterilizable substrate provides for a reusable mold. Glass was chosen as the ideal substrate for the non-implantable micro-molds, as it exhibits all of these characteristics. In addition, users can specify the thickness and dimensions of glass during manufacturing allowing for further customization of micro-molds. Glass also provides a low-cost solution, however, this material is not implantable.

**[0126]** For developing the mold housing, several properties in the substrate are necessary. The material chosen to build the mold housing should have the ability to be molded according to user specifications. This means it starts out as a liquid that can be poured into a mold and will set with time and temperature to form a solid feature surrounding the etched substrate. The polymer is preferably sterilizable. It is typically hydrophobic to prevent liquids from leaking out of the molds. Sylgard 184 Polydimethylsiloxane (PDMS) is ideal for these molds. It can be sterilized, is hydrophobic, can be easily poured in a mold and cured to a solid product. In addition, it can be used in temperature ranging from  $-45$  to  $200^\circ\text{C}$  over a long period of time, allowing for both freezing and steam-sterilization. PDMS has a working time of about 2 hours and can then be cured at room temperature ( $\sim 48$  hrs) or heat-cured (up to roughly  $200^\circ\text{C}$ ). PDMS mixed to manufacture specifications has the ability to stick to the glass substrate, further protecting from leakage of liquids in the mold (Mata et al, 2005). Micro-molds designed with glass and PDMS were specifically designed for *in vitro* experimentation and are not suited for *in vivo* use. Implantable molds that would be used for *in vivo* purposes are described below that do not use photolithography, but rather are produced by first making a negative stamp.

**[0127]** The micro-mold prototypes generated thus far were comprised of glass substrate in which divots were etched. The divot substrate can be cut to meet the needs of the user. For example, the substrate might be cut to the size of a standard microscope slide. In one prototype created thus far the soda-lime glass substrate was cut circularly to 33 mm diameter and 3 mm thick.

**[0128]** *Preparation of substrate surface.* The surface of the substrate to be divoted was cleaned with nitrogen gas to

remove large particles. Acid and base piranha solutions were used to deep clean the substrate to remove organic compounds and matter that could interfere with metal deposition and photolithography. Subsequently, the substrate was baked for 30-60 minutes. Other methods to remove large particles and organic compounds from surface substrates can be employed by a skilled artisan. Once the substrate surface was clean, a layer of metal (300 nm chromium) was sputtered on to the substrate using a Lesker Thin Film Deposition System. Alternative techniques for applying thin metal layers to substrate are known in the art and can be utilized.

**[0129] Photolithography.** A coat of AZ1518 Positive Photoresist (1 ml) was applied to the top of the deposited metal using a Spin Coater (Brewer CEE100 Programmable Spin Coater). The spin coater was set to yield a 1.8 micron layer of photoresist, followed by a soft bake at 100°C for 2 minutes. After cooling, the glass with the photomask was exposed to UV light (ABM UV Flood & Mask Alignment System) for 4 seconds followed by immersion in an AZ 300 MIF Developer for 30 seconds. The substrate was agitated slightly. The substrate was then baked at 100°C for 8-10 minutes. The developed pattern in the photoresist was subsequently etched into the chromium layer by immersing it in an CR7S Chromium Etchant with agitation to aid in the etching process. 30-45 seconds of immersion is required for the image to appear. The substrate was washed lightly with water and dried with nitrogen to prepare for the wet etching process. This produced a piece of glass layered with chromium and photoresist that contained open spots on the surface where chromium or photoresist were not present. These unmasked spots expose the glass surface to the wet etching process, while areas covered with chromium and photoresist protect the glass surface from the etching solution. This leads to etching of divots in the unmasked areas. Wet etching was completed in a solution of HF:HNO<sub>3</sub>:H<sub>2</sub>O at a ratio of 20:14:66 respectively. The substrate was immersed in solution for 18 minutes while on an orbital shaker at low speed. During this immersion, the acid attacked the glass by reacting with SiO<sub>2</sub>, thus dissolving visible portions of the glass that were not covered with the chromium and photoresist masks, creating uniform divots on the surface (FIG. 11). This solution yields an approximate etching rate of 4 to 5 μm of depth per minute (dependent on freshness of solution). Agitation on an orbital shaker ensure uniform etching of surface.

**[0130]** The substrate was subsequently washed in calcium carbonate and then water to neutralize and remove the excess acid, and finally dried with nitrogen. If excess chromium remained on the substrate, additional immersion in Chromium Etchant and washing with acetone and water to remove any remains is required. Finally, the substrate was dried with nitrogen. Divot depth and diameter was measured using a profilometer (FIG. 12). In the prototypes created thus far, variability in the divot size has not been problematic; prototype divots measured +/- 10% of specified dimensions.

**[0131]** We envision two other prophetic methods that may be used to create molds:

**SU-8 Negative Molds:** In this embodiment, glass will be used again as the substrate. The glass undergoes a similar photolithography process as before, but the original design is altered to create a negative template mold, that can then be converted to a micro-mold, but pouring one of the listed biopolymers onto the stamp and allowing it to cure. Briefly, SU-8 photoresist is spin coated in a thick layer (thickness of layer should be equal to desired depth of divots). It is then soft baked, covered with a photomask (as described above) and exposed to UV light, baked again post-exposure, developed in an SU-8 developer, and finally exposed to a post-development bake. This yields a piece of glass that has negative projections of divots based on design specifications. This negative template will then be used to cast molds in a given biopolymer or PDMS by creating a mold imprint upon curing. The stamp will then be removed from the cured polymer. The finished polymer will resemble the PDMS/Glass micro-molds and will have divots of defined dimensions. One advantage of this procedure is that for drug testing or other applications, each divot can be labeled during the design step with a unique identifier (ex. text, numbers), and will be present in the finished molds as visible imprints by each divot (see FIG. 28). A more detailed process is described in the manufacturer's processing guidelines (SU-8 2000 - Permanent Epoxy Negative Photoresist, MicroChem, Newton, MA).

**Etched Metal Mold Negatives:** In this embodiment, polymer molds would be created using a metal casting mold. The metal casting may be manufactured by designing a 3-D model in CAD software. One possible design is provided in FIG 27. The metal is laser-etched to create a casting mold similar to the SU-8 molds described above. Polymer is poured over the metal casting and cured to create a new micromold. Again, if necessary, text or numbers can be incorporated into the 3-D model to label each divot as above, leaving a visible imprint.

**[0132]** The SU-8 and Etched Metal templates were developed to allow a method for producing molds from a given material for both *in vitro* and *in vivo* use. More specifically, these methods can utilize biopolymers to create molds that can be implanted. These methods should also allow for more detailed designs (such as divot labels) and more control in divot creation, shape and size (variability of divot measurements should be less than +/- 1% of specified dimensions). Adherent substrate surfaces are not in accordance with the appended claims.

**[0133] Construction of housing for divoted substrate.** The next step in constructing the micro-mold is developing a system in which the divoted surface will be placed and secured, and which will serve as a larger vessel for culturing (see PDMS "housing" in FIG. 10).

**[0134]** The base [6] and vertical walls [5] of the mold housing were built using Dow Corning Sylgard 184 Polydimethylsiloxane (PDMS) (FIG. 13). PDMS was mixed at a ratio of 10 parts base to 1 part curing agent in a 50 ml centrifuge tube (~2 hr working time). The tube was mixed well to thoroughly disperse the base and curing agent. A vortex can be used to aid in mixing during this process. The PDMS was centrifuged at 1000-1500 rpm for 1 minute to remove air bubbles. Materials other than PDMS can be used to construct suitable housing for the micro-mold. For example, materials appropriate for a micro-mold meant for multi-use *in vitro* applications include, but are not limited to, micro-molds that will be implanted (*in vivo* use) will be formed with both the divoted surface and the sides of the mold from biopolymers. However, the height of the sides will be minimal, and may be removed prior to transplantation to decrease the total volume of transplanted material.

**[0135]** Materials appropriate for a micro-mold purposed for *in vivo* applications include, but are not limited to poly(orthoesters), poly(anhydrides), poly(phosphoesters), poly(phosphazenes), and others. Other non-limiting materials include, for example, polysaccharides, polyesters (such as poly(lactic acid), poly(L-lysine), poly(glycolic acid) and poly(lactic-co-glycolic acid)), poly(lactic acid-co-lysine), poly(lactic acid-graft-lysine), polyanhydrides (such as poly(fatty acid dimer), poly(fumaric acid), poly(sebacic acid), poly(carboxyphenoxy propane), poly(carboxyphenoxy hexane), copolymers of these monomers and the like), poly(anhydride-co-imides), poly(amides), poly(ortho esters), poly(iminocarbonates), poly(urethanes), poly(organophosphazenes), poly(phosphates), poly(ethylene vinyl acetate), and other acyl substituted cellulose acetates and derivatives thereof, poly(caprolactone), poly(carbonates), poly(amino acids), poly(acrylates), polyacetals, poly(cyanoacrylates), poly(styrenes), poly(vinyl chloride), poly(vinyl fluoride), poly(vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, copolymers, polystyrene, and blends or co-polymers thereof). In certain preferred aspects, the biomaterials include polysaccharides, alginate, hydroxypropyl cellulose (HPC), Nisopropylacrylamide (NIPA), polyethylene glycol, polyvinyl alcohol (PVA), polyethylenimine, chitosan (CS), chitin, dextran sulfate, heparin, chondroitin sulfate, gelatin, etc., and their derivatives, copolymers, and mixtures thereof. Other suitable biomaterials include those nylon, hyaluronan, polytetrafluoroethylene, polyvinyl formamide, and others described in Vats et al., (2003); Wang et al., (1997); and Orive et al., (2003)].

Adherent substrate surfaces are not in accordance with the appended claims.

**[0136]** The shape of the mold housing was formed using a copper scaffold (FIG. 13). One large copper tube (1.75 inch diameter) [1], was placed, open side down, on a flat surface [4] (e.g., large square of glass wrapped in aluminum foil). PDMS was added to the center of the tube opening to a depth of 2 mm to form the base of the mold housing [6]. The entire structure was then baked for 45 minutes at 100°C in an oven. Following baking, the divoted substrate was placed, divot side up, in the center of the copper tube (hashed line depicts location of etched glass [4] relative to large copper tube) on top of the cured PDMS base [6].

**[0137]** A small amount of PDMS was added to the edges of the divoted substrate to fix it in the center of the cured PDMS base [6]. The structure was then baked for 30 minutes at 100°C. A small copper tube [2] (1 inch diameter) was centered on top of the etched substrate and PDMS was poured into the space between the large [1] and small [2] copper tubes. This step was done carefully to avoid spilling the PDMS into the center of the mold. The amount of PDMS poured into the space between the large [1] and small [2] copper tubes determines the height of the mold housing [5]. The height and width of the mold housing can be specified by the user. The micro-mold, including the copper housing scaffold, was then baked overnight (at least 12 hrs) at 100°C to fully cure the PDMS.

**[0138]** Following overnight baking, the copper scaffold setup was removed as follows. The entire structure [1-7] was cooled to shrink the PDMS, allowing removal of the mold from the copper tube scaffold. The exact time needed for cooling is dependent on temperature; 30-60 minutes at -20°C is sufficient. The bottom foil/glass layer [4] and small copper tube [2] were removed carefully. Next, the large copper tube [1] was separated from the micro-mold.

**[0139]** *Sterilization of the micro-mold.* Preferably, a divot-containing surface of the present invention is capable of being sterilized. In one embodiment, when the finished micro-mold is free of scaffolding, it can be washed and sterilized as necessary for use. Ethanol and steam sterilization are the preferred methods of sterilization, but other methods of sterilization known to the skilled artisan are suitable. When using PDMS in the micro-mold, acetone should not be used. Likewise, sterilization procedures that will compromise the integrity of the materials used in the divoted substrate or the mold housing should not be used. Sterilization allows the micro-mold to be used repeatedly for *in vitro* use. Obviously molds used for *in vivo* implantation would not have this requirement.

#### Cell reaggregation within micro-molds.

**[0140]** *Delivery of cells to micro-molds.* Single dispersed islet cells used to reaggregate the islets can be obtained from any source of islet cells. In this example, an animal pancreas was cannulated *in situ* via the common bile duct, and distended by pumping a cold solution of collagenase (Worthington, Lakewood, NJ) into the duct. Subsequently, the distended pancreas was excised, transferred to centrifuge tubes, and incubated for 30 min with gentle rotation at 37°C. The washed digest was then passed through a screen and sedimented in a refrigerated centrifuge. The resulting pellet was mixed with Histopaque (density 1.1085 g/ml, Sigma Diagnostics, St. Louis, MO) and centrifuged. Islets were then

cleaned of exocrine tissue by filtering through a 40 $\mu$ m screen with Hanks Balanced Salt Solution (HBSS) with 5% bovine calf serum, and placed into Petri dishes containing DMEM/F12 culture medium, 10% fetal bovine serum (FBS), EGF (20ng/mL) and 1% antibiotics. The islets were maintained overnight at 37°C with 5% CO<sub>2</sub>.

5 [0141] To disperse islets into single cells, isolated islets were digested to viable cell suspensions by placing them in a 50 ml centrifuge tube, centrifuging and transferring the pellet to a 1.5 ml microcentrifuge tube. After two washes with calcium-magnesium free HBSS, a mixture of nine parts calcium-magnesium free HBSS and 1 part papain (5 U/ml final concentration) was added. After incubation on a rotator at 37°C for 20 min, the islets were pipetted, dispersing them into single cells.

10 [0142] *Incubation of cells in micro-molds.* Single-dispersed cells were transferred to the micro-molds in specialized Aggregate Media (DMEM/F12 culture medium, with 10% fetal bovine serum (FBS), EGF (20ng/mL), ITS (1g/L), BSA (2g/L), Nicotinamide (10nmol/L), Exendin-4 (5nmol/L) and 1% antibiotics) (Kikugawa *et al.* 2009) for final culture. To this Aggregate Media, we have added high calcium conditions (2-4 mM), which enhances islet reaggregation. At the time of dispersion, an aliquot of cells are microscopically examined using a hemocytometer. The percentage of single cells versus doublets or triplets is determined. A successful cell dispersion is defined as having a minimum of 90% viable single cells with the other 10% comprising doublets and triplets. By knowing the density of cells in the dispersion via the cell count using the hemocytometer, we are able to estimate the number of cells per divot. However, we have also counted the cells/divot once the micro-molds have been loaded, which varied from experiment to experiment, based on the media cell density, but ranged from 20-150. The number of cells/divot can be manipulated based on the density of cells in the media that is loaded into the mold providing advantages to the user for controlling the ultimate size of the target 3D cellular structure.

20 [0143] The micro-molds were gently shaken then allowed to sit for 15 minutes so that the cells settled into individual divots. The islets were maintained at 37°C with 5% CO<sub>2</sub> for up to 9 days with media changes daily. Changing media in the micro-molds, with 60  $\mu$ m deep divots was accomplished easily by gently removing (with suction) the old media from near the mold wall, and gently pipetting in to the mold the fresh media.

25 [0144] *Reaggregation of cell clusters within micro-molds.* Initially the cells fell randomly onto the bottom of each well. The number of cells that settle into each divot is set by the density of cells in suspension. In order to determine cell density prior to loading the micro-mold, an aliquot of the islet cell suspension is removed and the cells/volume are counted under a microscope using a hemocytometer. Knowing the number of divots in the mold, and the target size of each reaggregated islet, the number of cells in the suspension can be concentrated or diluted depending on the starting cell density. If a mold contains 10,000 divots and the desired outcome is 100 cells/divot, then there must be 1,000,000 cells in the media loaded into the micro-mold. Figure 14 shows cells developing in a micro-mold starting on day 2 and advancing to day 5. Between days 3 and 4, the cells began to take on the 3-dimensional shape of a native islet. Islets that developed within divots were all limited to less than 90  $\mu$ m in diameter (mean diameter less than 50  $\mu$ m). This dimension is important as we have published data showing that 50  $\mu$ m is a critical size for ensuring nourishment to the core cells of the islet (Williams *et al.*, 2010). Islets greater than 50  $\mu$ m demonstrated core cell death, while those less than 50  $\mu$ m rarely demonstrated core cell death in culture. The curved bottom of each divot helped to draw the cells towards one another for optimal formation of the spherical reaggregated islets. Figure 14 shows the measurements taken of a single divot depth using a profilometer. The depth of this single divot is slightly greater than 60  $\mu$ m and the bottom is curved, which pushes the cells towards the center of the divot for aggregation.

30 [0145] Success in generating reaggregated islets of optimal size and shape is exemplified by results obtained from an early prototype. This early prototype comprised undivoted substrate surface area surrounding the field of divots (FIG. 15). When seeded, some cells fell onto the undivoted surface of the prototype micro-mold. While some of the cells that fell onto undivoted surfaces stayed in the form of single cells or grew into small cell clusters, others formed mega-islets; huge complexes that were not limited by the divot specifications (FIG. 15). Within this early prototype mold, cells isolated from the same animal, that were cultured in the same media, and reaggregated on the same substrate material produced two different cell reaggregates: i) those formed within divots formed small well-shaped islets, and ii) those formed on the flat surface unrestricted to the physical constraints of a divot formed large conglomerations of cells that are subject to poor diffusion properties. Some of the unrestricted islets grew to a size of 400 $\mu$ m in diameter. These results provide excellent proof-of-concept that physically restricting the reaggregation of cells results in optimally-sized islets.

35 [0146] Experimental data suggest that islets reaggregated in micro-molds demonstrate diffusion properties similar to those exhibited by native small islets. To determine the diffusion properties of islets reaggregated in micro-molds, reaggregated islets were exposed to media containing a fluorescent analogue of glucose (2-NBDG) for ten minutes. The fluorescent glucose analogue completely infiltrated to the core of the reaggregated islets indicating that the barrier to diffusion of glucose is relatively low (FIG. 26). In contrast, previous work showed that native large islets have significant barriers to diffusion that inhibit the infiltration and cellular uptake of glucose into the core of the islet, even after hours of exposure to 2-NBDG (Williams *et al.*, 2010). Collectively, these data indicate that islets reaggregated in micro-molds have low diffusion barriers relative to native large islets.

40 [0147] *Comparison of cells formed in micro-molds to those formed in commercially available multi-well plates.* The

results of reaggregating islets in the molds were compared to reaggregating islets in commercially available micro plates. The commercial plates contained square-shaped wells that measured 500 $\mu$ m in diameter. Dispersed islet cells were cultured in the commercial plates and islet-like clusters formed, as predicted. Several observations were made. First, the islet cells formed in commercial plates congregated and bound to each other in the corners of the wells where they could contact the walls. Figure 16 shows a typical example of the cells forming a reaggregated islet touching the side of the commercial well. These cells use contact guidance to reform.

**[0148]** Second, without limitations to the size, more and more cells bound together creating giant islets (some over 400  $\mu$ m in diameter) with poor viability. Without the small micro-molds to limit the number of cells within each well and the physical dimensions designed to optimally guide the shape of reaggregated islets, the resulting islets were very large and contained a high percentage of dead cells. In viability assays from islets reaggregated in the commercially-available plates, over 50% cell death was noted with 6 days of culture. In these large openings, cells often remained as singlets, showing poor cell viability. Those cells that were able to cluster along the wall or corner of the well never formed the spherical shapes indicative of native islets, and had poor viability.

**[0149]** Third, the clusters of cells that formed in commercial molds did not reaggregate into the spherical islet-like tissue that we were able to obtain using the micro-mold. The sphere-forming ability of the reaggregated islets is likely an important feature predictive of successful *in vitro* function. Most multi-well plates are manufactured with flat bottom wells and square sides as shown in Figure 16. Cells reaggregated in commercial plates such as these do not attach to one another in a native-reminiscent sphere, and therefore are less likely to function as efficiently as a native islet. Although 1536 well plates with rounded bottoms are commercially available, islet cells formed in any well 500  $\mu$ m in diameter would be too large to overcome diffusion barriers. These results support the notion that current commercially available molds are inappropriate substrates for optimal islet formation.

**[0150]** *Removal of reaggregated cell clusters from molds.* In some instances it is desirable to remove the reaggregated islet cells from the micro-mold in a manner that does not compromise the integrity or viability of the cells. This can be easily accomplished by gently placing a large pipette directly over the divots and applying suction. The reaggregated islets are removed from the divots with the media. Subsequent washing of the micro-mold with fresh media and pipetting directly over the divots will remove almost all reaggregated islets in the mold.

**[0151]** *Characterization of cell reagggregates formed in micro-molds.* Islets removed from the microplates were measured for size and viability. Native rat islets range from 20 - 350 $\mu$ m in diameter. When reaggregated within divots of the micro-mold (100  $\mu$ m diameter, 60  $\mu$ m deep), 100% of islets had diameter less than 90  $\mu$ m; the mean diameter per reaggregated islet was  $36.6 \pm 1.2$   $\mu$ m (confocal microscopy measurements of over 500 individual reaggregated islets). Originally, we found a few larger structures that we believed represented islets that were never fully digested to single cells and therefore never fell into the divots. Since then, greater care during the dispersion procedure has led to islet suspensions with 90% of the cells in singlets and the remaining cells predominantly in doublets or triplets. We estimate, using micro-mold patterns A and B (FIG. 17), that 85-90% of all aggregates obtained are below 90 $\mu$ m in diameter. For reasons not yet understood, some of the cells in the divots divided into multiple islets rather than forming one reaggregated islet per divot. Figure 18 shows an example of two reaggregated islets within one divot.

**[0152]** Morphologically, the reaggregated islets look identical to native islets of the same size. They are spherical in shape with a capsule-like external surface surrounding the islet, as can be seen in the FIG 29. In contrast, FIG 15 shows that cells aggregating without the micro-mold do not form spheres or an apparent capsule.

**[0153]** Viability experiments were completed on the reaggregated islets using apoptosis/necrosis cellular stains (Invitrogen, Vybrant Apoptosis Assay containing Yo-Pro-1 and propidium iodide). This double-labeling assay measures both membrane integrity and fragmentation of DNA. Reaggregated islets were incubated in the two labels for 1 hour using methods we have published previously (MacGregor et al., 2006; Williams et al., 2010). Subsequently islets were rinsed with PBS and placed in the Attolfluor Chamber on the Fluoview 300 confocal microscope. Reaggregated islets were optically sectioned and images from the center of the islet were stored for later analysis. The area within the islet containing stain was calculated as a percentage of the total islet area to determine viability. Viability measurements of 5 day old reaggregated islets demonstrated extremely high viability within the cells and revealed very few dead cells/islet. The overall viability of the reaggregated islets was 99.76% This value is higher than previously reported in the literature for native large and small islets, and for single islet cell dispersions (Williams et al., 2010; Song et al., 2009).

**[0154]** Figure 19 shows examples of typical islets stained for viability. In these tests, red staining indicates cell death from necrosis and green cell staining indicates cell death from apoptosis.

**[0155]** Figure 19A shows one of only a very few dead cells that were identified in the islets reaggregated in the micro-molds. The cell stained red is undergoing cell death due to necrosis. In isolated tissue, cell necrosis often occurs first. Only two apoptotic (green) cells were noted in 500 islets tested. In contrast, when cells from the same animal formed large mega-islets on the surface of the micro-mold, there were significant numbers of dead cells present throughout the mass. Figure 19B captures one plane of view with 23 dead cells. Adjustment of the focal plane of the microscope showed that more dead cells were present within all planes of the mass. Thus, cells reaggregated in the divots to islets of the correct proportions had very high viability, while cells allowed to reaggregate into large masses outside of the divots

showed significant cell death. These results support the success of the micro-mold, because the cells that landed on areas of the mold without divots had much poorer viability than those formed in divots.

**[0156]** The viability of all cells formed in micro-molds exceeded that of native large and small islets from the same animals (FIG. 20). Viability was compared between rat large, small and reaggregated islets using Invitrogen's Vybrant Apoptosis Assay, as described previously. Six days after isolation, there was some variability in the percentage of live cells in the two groups of native islets, however there were few dead cells in the reaggregated islets, leading to error bars to were too small to visually represent in the figure. Islets reaggregated in micro-molds exhibited approximately 10% higher viability than native small islets and approximately 40% higher viability than native large islets (FIG. 20).

**[0157]** *Cell populations generated from micro-molds.* There are three major types of cells present in native islets (both large and small) that comprise about 90% of the total cells in the islets. Alpha cells that secrete glucagon make up about 20% of all of the cells in the islet. Beta cells that produce insulin make up 60-65% of the total cell numbers, and delta cells that somatostatin comprise 5-10% of the islet cell composition. Islets engineered in the present micro-molds have been shown to contain alpha, beta and delta cells. For example, Figure 21 depicts two representative islets formed in the present micro-molds 6 days after reaggregation; beta cells are stained green, alpha cells are stained red, and delta cells are stained blue. These engineered islets appear to have a lower percentage of beta cells than the average native islet. However, when compared to native small islets, the cellular relative composition of alpha : beta : delta cells and their organization may resemble native small islets. Native rat large and small islets are organized with glucagon-positive and somatostatin-positive cells located on the outer layers of the islet. The insulin-positive cells are found in the center. As such, the percentage of insulin-positive cells (the beta cells) is less in the small islet, but each islet contains high quantities of insulin. Although we have not calculated the percentage of beta/alpha/and delta cells (insulin/glucagon/somatostatin-positive cells) in enough reaggregated islets to conclude definitively, it is likely that the percentage of beta cells compared to all other cells will resemble the native small islet. One important difference is that in the reaggregated islets, the alpha, beta and delta cells are organized in a random pattern with the cells dispersed throughout the reaggregated islet. This is the same organization noted in human islets (Hahn van Dorshe et al., 1988; Bosco et al., 2010). Thus, the reaggregated islets demonstrate a more random pattern of cell organization, reminiscent of native human islets.)

**[0158]** *Insulin production.* It was important to verify that islets engineered in micro-molds were able to produce new insulin molecules. Insulin is first synthesized as a precursor molecule, called proinsulin. Six day old reaggregated islets were stained for proinsulin levels to determine whether they were making new insulin. Figure 22 shows an example of a reaggregated islet stained for mature insulin (green) and proinsulin molecules (red). As expected, the beta cells are double labeled. The image shows that new insulin is being synthesized in the reaggregated islets, even six days in culture.

**[0159]** Islets are responsible for releasing insulin into the blood in response to high glucose exposure after eating a meal. The lack of insulin secretion is the cause for the inability of people with type 1 diabetes to maintain normal blood glucose levels. To determine cell response to glucose, islets reaggregated in the present micro-mold and native small islets were exposed to low glucose conditions (3 mM). Insulin secreted into the media by both islet types was collected and quantified (FIG. 23). In low glucose conditions (30 minutes), reaggregated islets released 100 times more insulin than the native small islet (native small islets produce more insulin than native large islets). When exposed to high glucose (20 mM), the reaggregated islets continued to secrete significantly more insulin than the native large or small islets. To confirm that the reaggregated islets were secreting insulin rather than leaking insulin we completed additional experiments using a small membrane impermeant dextran (10 kD). A molecule this size is small enough to pass through the nuclear pore complex on the nuclear envelope within the cell. However, the plasma membrane does not contain protein complexes able to pass molecules of this size. The dextran (20 mM) was added to media containing reaggregated islets and confocal images captured the inability of the dextran to enter the cells even after 4 hours of exposure, suggesting that the cells were not leaky or membrane-damaged. Additionally, if cells were in fact leaking insulin rather than secreting it, we should have observed higher levels of red or green staining during necrosis/apoptosis assays in the reaggregated islets shown in FIG. 22. Collectively, these data suggest that islets reaggregated in micro-molds do indeed produce higher quantities of insulin than their native small or large islet counterparts.

**[0160]** To our knowledge, insulin secretion at these levels from native or altered islet cells has not been reported, making our results extremely unique. The Weir group reported encapsulating small reaggregated islets into an alginate with high guluronic acid content (O'Sullivan et al, 2010). Weir created these islet aggregates by simply dispersing islets to single cells and then allowing them to reshape without restrictions. Weir's work showed that in normal oxygen levels their small islets released as much insulin as native islets, but in low oxygen the Weir islets released more insulin than native islets. However, Weir's best performing islets secreted 20 times less insulin than our islets reaggregated in micro-molds. The reason for the relative decline in insulin secretion by our reaggregated islets in high glucose is unknown at this time, and something that must be determined before the engineered islets can be transplanted into diabetic animals. In spite of the relative decline, the dramatic increase in insulin secretion in both low and high glucose conditions, compared to the native islets, is an important and unique attribute of the micro-mold reaggregation method.

**[0161]** *Additives to islets.* Alternative methods and materials that could be utilized with the process of reaggregating islets in micro-molds are nearly limitless. First, there are many molecules that could be incorporated into the engineered

islets at the time of reggregation. These include but are not limited to growth factors, immunomodulators, immunosuppressants, cytokines, chemokines, DMARDs (disease-modifying antirheumatic drugs), anti-inflammatories, and antibiotics. Molecules or miniature devices to increase oxygen tension at the transplant site could be incorporated into the reaggregated islets, especially if an implantable micro-mold substrate were used. Other non-limiting classes of molecules that could be added at the time of reaggregation includes drugs to induce insulin release, small molecules, peptides, proteins, antibodies (e.g. against CD11a, CD11b, CD11c, CD18), and nucleic acids (e.g. DNA or RNA).

**[0162]** *Discussion.* Our divoted micro-mold is unlike other scaffolds used in the art to reaggregate cells. Previously, others have attempted to use the hanging drop method to form islets (e.g., Lehmann et al, 2007). In the hanging drop method, cells are placed in solution, into a drop on a petri dish lid, which is then turned upside down so that the cells fall to the bottom of the hanging drop of solution, where they might form an islet. However, the hanging-drop method is time-consuming and prone to contamination because the media in the "drop" cannot be changed.

**[0163]** *Utility of micro-molds in vitro.* The present micro-mold can be designed to form cell aggregates *in vitro* for subsequent transplantation or for drug or device testing among other applications.

**[0164]** *Generating cells for transplant.* (Prophetic Example) A preferable micro-mold designed to generate cells for transplantation is a single device that is sterilizable, reusable, and does not leak media or cells when filled (FIG. 24). First, islets need to be isolated from the pancreas. The small healthy islets would be separated from the large islets. Large islets would be dispersed into single cells or doublets, which are loaded into the micro-mold. After 3-6 days in culture, the cells would be removed, mixed with the native small islets, and transplanted into the diabetic recipient.

**[0165]** Micro-mold A (FIG. 17A) is designed for islet reaggregation with divots that are 100 $\mu$ m in diameter with a 60 $\mu$ m depth. We have found that 60 $\mu$ m depth is optimal, as it allows for easy removal of the reaggregated islets from the divots. The divots are arranged in an alternating pattern so that there is minimal space between divots (FIG. 17A). The average distance between divots is less than 30 $\mu$ m.

**[0166]** The undivoted surface seen in Figure 15 would be entirely covered in divots in the envisioned micro-mold for generating cells for transplant. This arrangement allows for maximal space on the micro-mold to be used for divots - resulting in maximum numbers of reaggregates made per mold, and maximum efficiency such that any cell floating to the surface of the mold will likely fall into a divot, thus limiting the loss of viable cells for reaggregation.

**[0167]** The number of divots that can be obtained on one mold will vary with the size of the mold. A mold of approximately 1.5 inches in diameter, using the micro-mold A design (FIG. 17A), contains between 10,000-12,000 divots per mold. The spacing of the divots is also dependent on the needs of the mold. For reaggregation of tissue for transplantation, efficiency of the original tissue to the number of reaggregated islets is important. The greater the percentage of cells that fall into the divots, the better the efficiency in making the new islets. So our molds designed for islet transplantation have a divot spacing of 20-30 $\mu$ m.

**[0168]** *Drug screening.* (Prophetic Example) Drug screening using the micro-mold is based on the concept that cells arranged in a 3D structure, like a mini-tumor or small islet, will respond to their environment differently than cells grown or reaggregated flat in a dish. For example, mini-tumors or islets could be formed in the divots of the micro-molds, and then potential therapeutics, such as anti-cancer drugs, could be applied either individually to each divot, or added to the entire plate. One would then examine the formation of the 3D structures and note changes, such as decreased cell viability or cluster size, that would indicate an undesirable effect of the test chemical. In the first example, many different drugs could be tested on one piece of glass that is approximately 35 mm in length. With the second approach a single drug would be tested, but in one mold there would be many individual responses that could be quantified.

**[0169]** One possible quantification for cancer drug testing would be viability (live/dead stains), which could be done for each tumor. While testing potential cancer drugs using the micro-mold design is appealing, the mold would be useful for all drug testing that is best done on cells in a 3D arrangement.

**[0170]** Micro-mold B (FIG. 17B) is designed for delivery of individual interventions to each well. Thus, it would be applicable for drug testing. For this design the divots were approximately 180 $\mu$ m in diameter with 120 $\mu$ m of space between each divot. The spacing can be increased or decreased as needed. Figure 11 shows an image of the floor of micro-mold B with individual empty divots. Micro-mold B contains 2,700-3,000 divots per mold, many fewer than in design A. The spacing between the divots in design B is greater to ensure accurate drug delivery to only one divot. Specification of the divot pattern and spacing is set by the user and will depend on the drug delivery system used. Using the molds to test thousands of compounds on cells in each divot would allow the user to complete drug screening on 2000-3000 different drugs in a mold that is less than 2 inches in diameter (FIG. 24). High throughput drug screening utilizing each mold for a separate drug, would allow thousands of individual cell clusters to respond and be measured as individual responses rather than an average response. High throughput drug screening partnered with nano-delivery systems could be utilized such that each divot could contain a different drug for testing. Alternatively, one could collect data points from thousands of samples exposed to the same treatment and culture conditions (FIG. 24).

**[0171]** *Generation of non-islet cells.* (Prophetic Example) Molds can be designed for a variety of cell aggregation shapes including but not limited to, long neuronal pathways, glomerular-like filters, vessels, replacement alveoli, etc. Aggregation of stem cells or reprogrammed cells in a small, well defined shape such as the micro-mold would also be

an appropriate use of this invention.

**[0172]** One typical application would be the expansion and aggregation of cultured cell lines into the molds. In this case, cells in suspension would be loaded into the molds at an extremely low density ranging from 1-50 cells/divot (depending on the needs of the user). Cultured cell lines contain dividing cells, which would be allowed to grow in the divots for a length of time depending on the needs of the user. Other cells sources would include freshly dispersed cells from animals or humans. The process to load freshly-dispersed cells is similar to the general methods described for islets. The tissue of choice, for example a vessel, would be exposed to digestive enzymes until single cells or doublets were in suspension. The cells would be loaded into the mold at the density and in the media of choice by the user. Finally, stem cells could be programmed to produce various adult cell types. These cells could also be loaded into the micromolds to enhance 3D structure formation.

**[0173]** Utility of micro-molds *in vivo*. (Prophetic Example) The micro-molds described here are useful for *in vitro* applications.

Adherent substrate surfaces are not in accordance with the appended claims.

**[0174]** *Reaggregate islets in molds for transplantation*. (Prophetic Example) Micro-molds constructed from biopolymers can be used to generate an implantable product (FIG. 23). In such case, the micro-environment of the mold would be altered so that reaggregated islets would attach to the biopolymer and the entire "patch" would be transplanted into the recipient. The biopolymers described *supra* would be appropriate for generating such an implantable micro-mold. The divots in the mold could be used to create wells that would allow the cells to first settle into the divots where their reaggregation would be guided by the dimensions of the divot, and second to adhere to the biopolymer divot.

**[0175]** In order to create divots in the biopolymer, wax negatives would be designed using protocols known in the art (e.g., Dean et al. 2007). For molds that are implantable, the islets would be left in the mold and surgically placed into the recipient. Implantable molds would have a mold design with openings between the divots that would allow the infiltration of nerves and blood vessels to the islets. Furthermore, implantable materials could be impregnated with, for example, neuronal and vascular growth factors and the molds could also contain immunosuppressants to protect the islets from immune rejection.

**[0176]** Implantation of the mold with islets could be done using several published methods. The micro-molds could be placed into the peritoneal cavity as published by Qi et al, 2010. The abdominal cavity is opened under anesthesia and the mold would be gently placed into the subfascial space. Alternative sites for implantation of the micro-mold include subcutaneous insertion, especially following preconditioning to increase the vascular supply to the region as described by Veriter et al. 2010. In human transplantation, the islets are placed into the liver via the portal vein (Koh et al, 2010). With micro-molds, infusion through the portal vein would not be possible, but the molds could be placed in the liver or under the kidney capsule with more invasive surgery (MacGregor et al, 2006).

## REFERENCES

**[0177]**

SU-8 2000 - Permanent Epoxy Negative Photoresist, MicroChem, Newton, MA.

Balmurgan AN, Chang Y, Fung JJ, Trucco M, and Bottino R., Flexible management of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata, *Am J Transplantation* 3: 1135-1142, (2003).

Bosco D, Armanet M. Morel P, Niclauss N, Sgroi A, Muller YD, Giovannoni L, Parnaud G, Berney T, Unique arrangement of alpha- and beta-cells in human islets of Langerhans, *Diabetes*. Feb 25. [Epub ahead of print] (2010).

Chan CB, Saleh MC, Purje A, and MacPhail RM, Glucose-inducible hypertrophy and suppression of anion efflux in rat beta cells, *J Endocrinol* 173: 45-52, (2002).

Chan CB and Surette JJ, Glucose refractoriness of beta-cells from fed fa/fa rats is ameliorated by nonesterified fatty acids, *Can J Physiol Pharmacol* 77: 934-942, (1999).

Crim WS, Wu R, Carter JD, Cole BK, Trace AP, Mirmira RG, Kunsch C, Nadler JL, Nunemaker CS. AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. *Mol Cell Endocrinol*. Mar 6. [Epub ahead of print] (2010).

Cui Y-F, Ma M, Wang G-Y, D-E. H, Vollmar B, and Menger MD, Prevention of core cell damage in isolated islets of Langerhans by low temperature preconditioning, *World J Gastroenterol* 11: 545-550, (2005).

Dean et al., Comparison of insulin autoantibodies in diabetes-related and healthy populations by precise displacement ELM, *Diabetes* (1989).

5 Dean, D. M., Napolitano, A. P., Youssef, J., Morgan, J. R. (2007) Rods, tori, and honeycombs the directed self-assembly of microtissues with prescribed microscale geometries. *FASEB J.* 21, 4005-4012.

Dufrane D, Goebbels RM, Fdilat 1, Guiot Y, and Gianello P, Impact of porcine islet size on cellular structure and engraftment after transplantation: adult versus young pigs, *Pancreas* 30: 138-147, (2005).

10 Hahn von Dorsche, H., Reiher, H., Hahn. H.J., Phases in the early development of the human islet organ, *Anat Anz.*, 166(1-5):69-76 (1988).

Hutton JC and Malaisse WJ, Dynamics of O<sub>2</sub> consumption in rat pancreatic islets, *Diabetologia* 18: 395-405, (1980).

15 Kaihow T, Masuda T, Sasano N, and Takahashi T, The size and number of Langerhans islets correlated with their endocrine function: a morphometry on immunostained serial sectioned adult human pancreases, *Tohoku J Exp Med* 149: 1-10, (1986).

20 Kawashima Y, Yamamoto H, Takeuchi H and Kuno Y, Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin, *Pharm Dev Technol* 5:77-85 (2000).

Keegan M, Falcone J, Leung T and Saltzman WM, Biodegradable microspheres with enhanced capacity for covalently bound surface lipands, *Macromol* 37:9779-9784 (2004).

25 Kikugawa, R., H. Katsuta, et al. (2009). Differentiation of COPAS-sorted non-endocrinc pancreatic cells into insulin-positive cells in the mouse. *Diabetologia* 52(4): 645-52.

30 Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O, Shapiro AM. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success., *Transplantation*. 89(4):465-71, (2010).

Krickhahn M, Buhler C, Meyer T, Thiede A, and Ulrichs K, The morphology of islets within the porcine donor pancreas determines the isolation result: successful isolation of pancreatic islets can now be achieved from young market pigs, *Cell Transplant* 11: 827-838, (2002).

35 Lehmann R, Zuellig RA, Kugelmeier P, Bainninger PB, Moritz W, Perren A, Claviens P-A, Weber M, Spinass GA, Superiority of Small Islets in Human Islet Transplantation. *Diabetes* 56, 504-603 (2007).

40 Mata A, Fleischman AJ, Roy S, Characterization of Polydimethylsiloxane (PDMS) Properties for Biomedical Micro/Nanosystems, *Biomedical Microdevices* 7(4): 281-293 (2005),

Mattson G, Jansson L, and Carlsson P-O, Decreased vascular density in mouse pancreatic islets after transplantation, *Diabetes* 51: 1362-1366, (2002).

45 Menger MD, Jaeger S, Walter P, Feifel G, Hammersen F, and Messmer K, Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans, *Diabetes* 38 Suppl: 199-201, (1989).

O'Sullivan ES, Johnson AS, Omer A, Hollister-Lock J, Bonner-Weir S, Colton CK, Weir GC. (2010) Rat islet cell aggregates are superior to islets for transplantation in microcapsules. *Diabetologia* 2010 Jan 26. [Epub ahead of print].

50 Petropavlovskaja M and Rosenberg L, Identification and characterization of small cells in the adult pancreas: potential progenitor cells?, *Cell Tissue Res* 310: 51-58, (2002).

55 Qi Z, Shen Y, Yanai G, Yang K, Shirouzu Y, Hiura A, Sumi S. The in vivo performance of polyvinyl alcohol macro-encapsulated islets. *Biomaterials*. 31(14):4026-31, (2010).

Ritz-Laser B, Oberholzer J, Toso C, Brulhart MC, Zakrzewska K, Ris F, Bucher P, Morel P, and Philippe J, Molecular detection of circulating beta-cells after islet transplantation, *Diabetes* 51: 557-561, (2002).

Scharp DW, Lacy PE, Santiago J, McCullough C, Weide LG, Falqui L, Marchetti P, Gingerich R, Jaffe A, Cryer P, Anderson C, and Flye W, Insulin independence following islet transplantation into patient with Type 1, insulin dependent diabetes mellitus, *Diabetes* 39: 515-518, (1990).

5 Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Knetman NM, and Rajotte RV, Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regime, *New England J Med* 343: 230-238, (2000).

10 Song HJ, Xue WJ, Li Y, Tian XH, Song Y, Ding XM, Feng XS, Tian PX, Li ZL., Improved islet survival and function with rat endothelial cells in vitro co-culture. *Transplant Proc.* Dec;41(10):4302-6, (2009).

Sutherland DE, Gores PF, Farney AC, Wahoff DC, Matas AJ, Dunn DL, Gruessner RW, and Najarian JS, Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota, *Am J Surg* 166: 456-491, (1993).

15 Sweet IR, Khalil G, Wallen AR, Steedman M, Schenkman KA, Reems JA, Kahn SE, and Callis JB, Continuous measurement of oxygen consumption by pancreatic islets, *Diabetes Technol Ther* 4: 661-672, (2002).

20 Tatariewicz K, Garcia M, Lopez-Avalos M, Bonner-Weir S, and Weir GC. Porcine neonatal pancreatic cell clusters in tissue culture: benefits of serum and immobilization in alginate hydrogel, *Transplantation* 71: 15181526, (2001).

Vériter S, Mergen J, Goebbels RM, Auouassar N, Grégoire C, Jordan B, Levêque P, Gallez B, Gianello P, Dufrane D. In Vivo Selection of Biocompatible Alginates for Islet Encapsulation and Subcutaneous Transplantation, *Tissue Eng Part A.* Feb 11, [Epub ahead of print], (2010).

25 von Mach MA, Schlosser S, Weiland M, Feilen FJ, Ringel M, Hengstler JG, Weilemann LS, Beyer J, Kann P, and Schneider S, Size of pancreatic islets of Langerhans: a key parameter for viability after cryopreservation, *Acta Diabetol* 40: 123-129, (2003).

30 Warnock GL, Ellis DK, Cattral M, Untch D, Kneteman NM, and Rajotte RV, Viable purified islets of Langerhans from collagenase-perfused human pancreas, *Diabetes* 38:136-139 (1989).

35 Williams, SJ., Wang, MacGregor, R., Q., Siahaan, T., Stehno-Bittel, L., Berkland, C. (2009) Adhesion of pancreatic beta cells to biopolymer films, *Biopolymers*, 91(8):676-685.

Williams SJ, Huang H, Kover K, Moore W, Berkland C, Singh M, Stehno-Bittel L, Reduction of Diffusion Barriers in Isolated Islets Improves Survival, But Not Insulin Secretion, *Organogenesis*, in press (2010).

40 Xu W, McDough RC, Langsdorf B, Demas 1N, and DeGraff BA, Oxygen sensors based on luminescence quenching: interaction metal complexes with the polymer supports, *Anal Chem* 66: 4133-4141 (1994).

## Claims

45 1. A surface for culturing cells comprising:

a substrate comprising a substantially planar top surface, wherein the surface comprises a plurality of divots; wherein each divot comprises an interior bottom surface and an interior sidewall surface, wherein the bottom surface is rounded and wherein each divot is between 100-200  $\mu\text{m}$  in diameter ( $\pm 20\%$ ) and 50-150  $\mu\text{m}$  in depth ( $\pm 20\%$ );  
50 wherein cells are distributed into individual divots, and wherein the substrate surface is a non-adherent surface.

2. The device of claim 1 additionally comprising a system for holding said planar surface, wherein the system forms a bottom surface and an interior side wall surface and an interior volume, the bottom and side walls being substantially tight to liquids, wherein cells and culture medium are distributed into the interior volume.

55 3. The device of claim 1, wherein the cells are islet cells or non-islet cells.

4. The device of claim 1, wherein the planar surface is made of glass.
5. The device of claim 1, said substrate being an etched substrate comprising the divots etched into the substantially planar top surface of the substrate.
- 5 6. A method for culturing cells comprising introducing cells to a surface comprising: a substrate comprising a substantially planar top surface, wherein the surface comprises a plurality of divots, wherein each divot comprises an interior bottom surface and an interior sidewall surface, wherein the bottom surface is rounded and wherein each divot is between 100 - 200  $\mu\text{m}$  in diameter ( $\pm 20\%$ ) and 50 - 150  $\mu\text{m}$  in depth ( $\pm 20\%$ ), wherein cells are distributed into individual divots and the wherein the substrate surface is a non-adherent surface; and exposing the surface to cell culture conditions.
- 10 7. The method of claim 6 wherein the cells are islet cells or non-islet cells and wherein the cells aggregate into 3-dimensional cell aggregates after exposure to the device and supportive culture conditions.
- 15 8. The method of claim 6 wherein the cells are dispersed from an islet culture and chemicals or biological molecules are incorporated into the resulting small islets.
- 20 9. The method of claim 6, further comprising introducing a test chemical to each divot, and analyzing the response of the cells to the test chemical.
- 25 10. The method of claim 6, wherein the cells settle into the divots in an approximately 20-150 cells per 1 divot ratio.

25 **Patentansprüche**

1. Oberfläche zum Kultivieren von Zellen, umfassend:

30 ein Substrat, umfassend eine im Wesentlichen ebene obere Oberfläche, wobei die Oberfläche mehrere Vertiefungen umfasst;  
wobei jede Vertiefung eine innere Bodenfläche und eine innere Seitenwandfläche umfasst, wobei die Bodenfläche abgerundet ist und wobei jede Vertiefung einen Durchmesser von 100 - 200  $\mu\text{m}$  ( $\pm 20\%$ ) und eine Tiefe von 50 - 150  $\mu\text{m}$  ( $\pm 20\%$ ) aufweist;  
wobei Zellen in einzelnen Vertiefungen verteilt sind und wobei die Substratoberfläche eine nicht haftende Oberfläche ist.

35

2. Vorrichtung nach Anspruch 1, zusätzlich umfassend ein System zum Halten der ebenen Oberfläche, wobei das System eine Bodenfläche und eine innere Seitenwandfläche und ein Innenvolumen bildet, wobei die Boden- und Seitenwände im Wesentlichen flüssigkeitsdicht sind, wobei Zellen und Kulturmedium in das Innenvolumen verteilt sind.
- 40
3. Vorrichtung nach Anspruch 1, wobei die Zellen Inselzellen oder Nicht-Inselzellen sind.
4. Vorrichtung nach Anspruch 1, wobei die ebene Oberfläche aus Glas besteht.
- 45
5. Vorrichtung nach Anspruch 1, wobei das Substrat ein geätztes Substrat ist, das die Vertiefungen umfasst, die in die im Wesentlichen ebene obere Oberfläche des Substrats geätzt sind.
- 50 6. Verfahren zum Kultivieren von Zellen, umfassend ein Zuleiten von Zellen zu einer Oberfläche, umfassend: ein Substrat, umfassend eine im Wesentlichen ebene obere Oberfläche, wobei die Oberfläche mehrere Vertiefungen umfasst; wobei jede Vertiefung eine innere Bodenfläche und eine innere Seitenwandfläche umfasst, wobei die Bodenfläche abgerundet ist und wobei jede Vertiefung einen Durchmesser von 100 - 200  $\mu\text{m}$  ( $\pm 20\%$ ) und eine Tiefe von 50 - 150  $\mu\text{m}$  ( $\pm 20\%$ ) aufweist; wobei Zellen in einzelnen Vertiefungen verteilt sind und wobei die Substratoberfläche eine nicht haftende Oberfläche ist; und Aussetzen der Oberfläche Zellkulturbedingungen.
- 55 7. Verfahren nach Anspruch 6, wobei die Zellen Inselzellen oder Nicht-Inselzellen sind und wobei die Zellen zu dreidimensionalen Zellaggregaten aggregieren, nachdem sie den Vorrichtungs- und unterstützenden Kulturbedingungen ausgesetzt worden sind.

8. Verfahren nach Anspruch 6, wobei die Zellen von einer Inselkultur dispergiert werden und Chemikalien oder biologische Moleküle in die resultierenden kleinen Inseln eingegliedert sind.
- 5 9. Verfahren nach Anspruch 6, ferner umfassend ein Zuleiten einer Testchemikalie in jede Vertiefung und Analysieren der Reaktion der Zellen auf die Testchemikalie.
10. Verfahren nach Anspruch 6, wobei die Zellen sich in den Vertiefungen in einem Verhältnis von etwa 20 - 150 Zellen pro 1 Vertiefung absetzen.

10

### Revendications

1. Une surface pour la culture de cellules comprenant :

15

un substrat comprenant une surface supérieure sensiblement plane, dans laquelle la surface comprend une pluralité de mottes de gazon ;  
dans laquelle chaque motte de gazon comprend une surface de fond intérieure et une surface de paroi latérale intérieure, dans laquelle la surface de fond est arrondie et dans laquelle chaque motte de gazon est comprise entre 100-200  $\mu\text{m}$  de diamètre ( $\pm 20\%$ ) et 50-150  $\mu\text{m}$  de profondeur ( $\pm 20\%$ ) ;  
20 dans laquelle les cellules sont réparties en mottes de gazon individuelles, et dans laquelle la surface du substrat est une surface non-adhérente.

20

2. Le dispositif selon la revendication 1 comprenant en outre un système pour maintenir ladite surface plane, dans lequel le système forme une surface de fond et une surface de paroi latérale intérieure et un volume intérieur, les parois de fond et latérales étant sensiblement étanches aux liquides, dans lequel les cellules et le milieu de culture sont répartis dans le volume intérieur.

25

3. Le dispositif selon la revendication 1, dans lequel les cellules sont des cellules d'îlots ou autres que des cellules d'îlots.

30

4. Le dispositif selon la revendication 1, dans lequel la surface plane est en verre.

5. Le dispositif selon la revendication 1, ledit substrat étant un substrat gravé comprenant les mottes de gazon gravées sur la surface supérieure sensiblement plane du substrat.

35

6. Un procédé de culture de cellules comprenant l'introduction de cellules sur une surface comprenant : un substrat comprenant une surface supérieure sensiblement plane, dans lequel la surface comprend une pluralité de mottes de gazon, dans lequel chaque motte de gazon comprend une surface de fond intérieure et une surface de paroi latérale intérieure, dans lequel la surface de fond est arrondie et dans lequel chaque motte de gazon est comprise entre 100-200  $\mu\text{m}$  de diamètre ( $\pm 20\%$ ) et 50-150  $\mu\text{m}$  de profondeur ( $\pm 20\%$ ), dans lequel les cellules sont réparties en mottes de gazon individuelles et dans lequel la surface du substrat est une surface non adhérente ; et l'exposition de la surface aux conditions de culture cellulaire.

40

7. Le procédé selon la revendication 6, dans lequel les cellules sont des cellules d'îlots ou autres que des cellules d'îlots et dans lequel les cellules s'agrègent en agrégats cellulaires tridimensionnels après exposition au dispositif et aux conditions de culture de soutien.

45

8. Le procédé selon la revendication 6, dans lequel les cellules sont dispersées à partir d'une culture d'îlots et des produits chimiques ou des molécules biologiques sont incorporés dans les petits îlots résultants.

50

9. Le procédé selon la revendication 6, comprenant en outre l'introduction d'un produit chimique d'essai dans chaque motte de gazon, et l'analyse de la réponse des cellules au produit chimique d'essai.

10. Le procédé selon la revendication 6, dans lequel les cellules se déposent dans les mottes de gazon selon un rapport d'environ 20-150 cellules pour 1 motte de gazon.

55




FIG. 1




FIG. 2




FIG. 3a




FIG. 3b




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8


**Thickness**

**Patch Cross-Section**


**1-2 islet  
cells**



**2 islet  
cells**



**3-4 islet  
cells**



**4-5 islet  
cells**




FIG. 9




FIG. 10





FIG. 11

FIG. 12







FIG. 13



Day 2

Day 5

FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27





FIG. 28




FIG. 29

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 6703017 B, Peck [0007]
- WO 9300411 A, Brothers [0007]
- WO 8601530 A, Neilsen [0007]
- EP 0363125 A, Zayas [0007]
- US 2008103606 A [0008]
- WO 03044164 A [0008]
- EP 2286822 A [0008]
- US 5710172 A [0058]
- US 5696109 A [0058]
- US 5670545 A [0058]
- US 20050107585 A, Murray [0061]
- US 6783954 B [0095]

## Non-patent literature cited in the description

- **SUTHERLAND et al.** Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. *Am. J. Surg.*, 1993, vol. 166, 456-491 [0003]
- **RIDGWAY et al.** Pancreatic islet cell transplantation: progress in the clinical setting. *Treat. Endocrinol.*, 2003, vol. 2 (3), 173-189 [0003]
- **SHAPIRO et al.** Clinical results after islet transplantation. *J. Investig. Med.*, 2001, vol. 49 (6), 559-562 [0003]
- **BALAMURUGAN et al.** Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. *Pancreas*, 2006, vol. 32 (3), 231-243 [0003]
- **BONNEVIE-NIELSEN et al.** Pancreatic islet volume distribution: direct measurement in preparations stained by perfusion in situ. *Acta Endocrinol. (Copenh)*, 1984, vol. 105 (3), 379-84 [0004]
- **DULONG et al.** Contributions of a finite element model for the geometric optimization of an implantable bioartificial pancreas. *Artif. Organs*, 2002, vol. 26 (7), 583-9 [0005]
- **GIULIANA et al.** Central necrosis in isolated hypoxic human pancreatic islets; evidence for postisolation ischemia. *Cell Transplantation*, 2005, vol. 147, 67-76 [0005]
- **MACGREGOR et al.** Small rat islets are superior to large islets in in vitro function and in transplantation outcomes. *Am. J. Physiol. Endocrinol. Metab.*, 2006, vol. 290 (5), E771-779 [0005] [0116]
- **BOTTINO et al.** Response of human islets to isolation stress and the effect of antioxidant treatment. *Diabetes*, 2004, vol. 53 (10), 2559-68 [0005]
- **KAURI et al.** Direct measurement of glucose gradients and mass transport within islets of Langerhans. *Biochem. Biophys. Res. Commun.*, 2003, vol. 304 (2), 371-7 [0006]
- **BONE et al.** Microcarriers; A New Approach to Pancreatic Islet Cell Culture. *In Vitro*, February 1982, vol. 18 (2) [0007]
- **CHOI et al.** *Biomaterials*, 2010, vol. 31 (15), 4296-4303 [0008]
- **VATS et al.** Scaffolds and biomaterials for tissue engineering: a review of clinical applications. *Clin. Otolaryngol. Allied Sci.*, 2003, vol. 28 (3), 165-72 [0047]
- **WANG et al.** An encapsulation system for the immunisolation of pancreatic islets. *Nat. Biotechnol.*, 1997, vol. 15 (4), 358-62 [0047]
- **ORIVE et al.** Cell encapsulation: promise and progress. *Nat. Med.*, 2003, vol. 9 (1), 104-7 [0047]
- **BERKLAND et al.** Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. *J. Control. Release*, 18 May 2001, vol. 73 (1), 59-74 [0048]
- **DUNEHOO et al.** Cell adhesion molecules for targeted drug delivery. *J. Pharm. Sci.*, 2006, vol. 95, 1856-1872 [0050]
- **HAUGE-EVANS et al.** Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced Ca<sup>2+</sup> and insulin secretory responses of MINE pseudoislets. *Diabetes*, 1999, vol. 48, 1402-1408 [0050]
- **MIAO et al.** In vitro and in vivo improvement of islet survival following treatment with nerve growth factor. *Transplantation*, 27 February 2006, vol. 81 (4), 519-24 [0055]
- **TA et al.** The defined combination of growth factors controls generation of long-term replicating islet progenitor-like cells from cultures of adult mouse pancreas. *Stem Cells*, 23 March 2006 [0055]
- **JOHANNSON.** Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. *Endocrinology*, May 2006, vol. 147(5) (23), 15-24 [0055]
- **KUNTZ et al.** Effect of epiregulin on pancreatic beta cell growth and insulin secretion. *Growth Factors*, 23 December 2005, (4), 285-93 [0055]

- **VASADAVA.** Growth factors and beta cell replication. *Int. J. Biochem. Cell Biol.*, 2006, vol. 38 (5- 6), 931-50 [0055]
- **KUNTZ et al.** Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. *JOP*, 10 November 2004, vol. 5(6), 464-75 [0055]
- **YUSUF-MAKAGIANSAR et al.** inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-I as a therapeutic approach to inflammation and autoimmune diseases. *Medicinal Chemistry Reviews*, 2002, vol. 22, 146-167 [0061]
- **ANDERSON ; SIAHAAN.** Targeting 1CAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors. *Peptides*, 2003, vol. 24, 487-501 [0061]
- **TISCH et al.** Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in non-obese diabetic mice. *Diabetes*, 1998, vol. 47, 894-899 [0061]
- **RAMAN et al.** Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. *J. Control. Release.*, 02 March 2005, vol. 103 (1), 149-58 [0063]
- **BERKLAND et al.** Precise control of PLG microsphere size provides enhanced control of drug release rate. *J. Control. Release.*, 18 July 2002, vol. 82 (1), 137-47 [0063]
- **SCHWENDEMAN.** Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. *Crit. Rev. Ther. Drug Carrier Syst.*, 2002, vol. 19 (1), 73-98 [0063]
- **SERSHEN et al.** Implantable, polymeric systems for modulated drug delivery. *Adv. Drug Deliv. Rev.*, 2002, vol. 5;54 (9), 1225-1235 [0063]
- **MACGREGOR et al.** Small rat islets are superior to large islets in in vitro function and in transplantation outcomes. *Am. J. Physiol. Endocrinol. Metab.*, February 1990, (5), E771-9 [0082]
- **BALAMURUGAN et al.** Flexible management of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata. *Am. J. Transplant*, 2003, vol. 3 (9), 113542 [0097]
- **HAUGE-EVANS et al.** Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced Ca<sup>2+</sup> and insulin secretory responses of MIN6 pseudoislets. *Diabetes*, 1999, vol. 48 (7), 1402-8 [0099]
- **MYTHILI et al.** Culture prior to transplantation preserves the ultrastructural integrity of monkey pancreatic islets. *J. Electron Microsc.*, 2003, vol. 52 (4), 399-405 [0100]
- **BALMURGAN AN ; CHANG Y ; FUNG JJ ; TRUCO M ; BOTTINO R.** Flexible management of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata. *Am J Transplantation*, 2003, vol. 3, 1135-1142 [0177]
- **BOSCO D ; ARMANET M ; MOREL P ; NICLAUSS N ; SGROI A ; MULLER YD ; GIOVANNONI L ; PARNAUD G ; BERNEY T.** Unique arrangement of alpha- and beta-cells in human islets of Langerhans. *Diabetes*, 25 February 2010 [0177]
- **CHAN CB ; SALEH MC ; PURJE A ; MACPHAIL RM.** Glucose-inducible hypertrophy and suppression of anion efflux in rat beta cells. *J Endocrinol*, 2002, vol. 173, 45-52 [0177]
- **CHAN CB ; SURETTE JJ.** Glucose refractoriness of beta-cells from fed fa/fa rats is ameliorated by non-esterified fatty acids. *Can J Physiol Pharmacol*, 1999, vol. 77, 934-942 [0177]
- **CRIM WS ; WU R ; CARTER JD ; COLE BK ; TRACE AP ; MIRMIRA RG ; KUNSCH C ; NADLER JL ; NUNEMAKER CS.** AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. *Mol Cell Endocrinol.*, 06 May 2010 [0177]
- **CUI Y-F ; MA M ; WANG G-Y ; D-E. H ; VOLLMAR B ; MENDER MD.** Prevention of core cell damage in isolated islets of Langerhans by low temperature preconditioning. *World J Gastroenter*, 2005, vol. 11, 545-550 [0177]
- **DEAN et al.** Comparison of insulin autoantibodies in diabetes-related and healthy populations by precise displacement ELM. *Diabetes*, 1989 [0177]
- **DEAN, D. M. ; NAPOLITANO, A. P. ; YOUSSEF, J. ; MORGAN, J. R.** Rods, tori, and honeycombs the directed self-assembly of microtissues with prescribed microscale geometries. *FASEB J.*, 2007, vol. 21, 4005-4012 [0177]
- **DUFRANE D ; GOEBBELS RM ; FDILAT 1 ; GUIOT Y ; GIANELLO P.** Impact of porcine islet size on cellular structure and engraftment after transplantation: adult versus young pigs. *Pancreas*, 2005, vol. 30, 138-147 [0177]
- **HAHN VON DORSCH, H. ; REIHER, H. ; HAHN. H.J.** Phases in the early development of the human islet organ. *Anat Anz.*, 1988, vol. 166 (1-5), 69-76 [0177]
- **HUTTON JC ; MALAISSE WJ.** Dynamics of O2 consumption in rat pancreatic islets. *Diabetologia*, 1980, vol. 18, 395-405 [0177]
- **KAIHOW T ; MASUDA T ; SASANO N ; TAKAHASHI T.** The size and number of Langerhans islets correlated with their endocrine function: a morphometry on immunostained serial sectioned adult human pancreases. *J Exp Med*, 1986, vol. 149, 1-10 [0177]
- **KAWASHIMA Y ; YAMAMOTO H ; TAKEUCHI H ; KUNO Y.** Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. *Pharm Dev Technol*, 2000, vol. 5, 77-85 [0177]
- **KEEGAN M ; FALCONE J ; LEUNG T ; SALTZMAN WM.** Biodegradable microspheres with enhanced capacity for covalently bound surface lipands. *Macromol*, 2004, vol. 37, 9779-9784 [0177]

- **KIKUGAWA, R. ; H. KATSUTA et al.** Differentiation of COPAS-sorted non-endocrine pancreatic cells into insulin-positive cells in the mouse. *Diabetologia*, 2009, vol. 52 (4), 645-52 [0177]
- **KOH A ; SENIOR P ; SALAM A ; KIN T ; IMES S ; DINYARI P ; MALCOLM A ; TOSO C ; NILSSON B ; KORSGRENO.** Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. *Transplantation*, 2010, vol. 89 (4), 465-71 [0177]
- **KRICKHAHN M ; BUHLER C ; MEYER T ; THIEDE A ; ULRICHS K.** The morphology of islets within the porcine donor pancreas determines the isolation result: successful isolation of pancreatic islets can now be achieved from young market pigs. *Cell Transplant*, 2002, vol. 11, 827-838 [0177]
- **LEHMANN R ; ZUELLIG RA ; KUGELMEIER P ; BAINNINGER PB ; MORITZ W ; PERREN A ; CLAVIENS P-A ; WEBER M ; SPINAS GA.** Superiority of Small Islets in Human Islet Transplantation. *Diabetes*, 2007, vol. 56, 504-603 [0177]
- **MATA A ; FLEISCHMAN AJ ; ROY S.** Characterization of Polydimethylsiloxane (PDMS) Properties for Biomedical Micro/Nanosystems. *Biomedical Microdevices*, 2005, vol. 7 (4), 281-293 [0177]
- **MATTSON G ; JANSSON L ; CARLSSON P-O.** Decreased vascular density in mouse pancreatic islets after transplantation. *Diabetes*, 2002, vol. 51, 1362-1366 [0177]
- **MENGER MD ; JAEGER S ; WALTER P ; FEIFEL G ; HAMMERSEN F ; MESSMER K.** Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans. *Diabetes*, 1989, vol. 38 (199-201 [0177]
- **O'SULLIVAN ES ; JOHNSON AS ; OMER A ; HOLLISTER-LOCK J ; BONNER-WEIR S ; COLTON CK ; WEIR GC.** Rat islet cell aggregates are superior to islets for transplantation in microcapsules. *Diabetologia*, 26 January 2010 [0177]
- **PETROPAVLOVSKAIA M ; ROSENBERG L.** Identification and characterization of small cells in the adult pancreas: potential progenitor cells?. *Cell Tissue Res*, 2002, vol. 310, 51-58 [0177]
- **QI Z ; SHEN Y ; YANAI G ; YANG K ; SHIROUZU Y ; HIURA A ; SUMI S.** The in vivo performance of polyvinyl alcohol macro-encapsulated islets. *Biomaterials*, 2010, vol. 31 (14), 4026-31 [0177]
- **RITZ-LASER B ; OBERHOLZER J ; TOSO C ; BRULHART MC ; ZAKRZEWSKA K ; RIS F ; BUCHER P ; MOREL P ; PHILIPPE J.** Molecular detection of circulating beta-cells after islet transplantation. *Diabetes*, 2002, vol. 51, 557-561 [0177]
- **SCHARP DW ; LACY PE ; SANTIAGO J ; MCCULLOUGH C ; WEIDE LG ; FALQUI L ; MARCHETTI P ; GINGERICH R ; JAFFE A ; CRYER P.** Insulin independence following islet transplantation into patient with Type 1, insulin dependent diabetes mellitus. *Diabetes*, 1990, vol. 39, 515-518 [0177]
- **SHAPIRO AM ; LAKEY JR ; RYAN EA ; KORBUTT GS ; TOTHE E ; WARNOCK GL ; KNETMAN NM ; RAJOTTE RV.** Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regime. *New England J Med*, 2000, vol. 343, 230-238 [0177]
- **SONG HJ ; XUE WJ ; LI Y ; TIAN XH ; SONG Y ; DING XM ; FENG XS ; TIAN PX ; LI ZL.** Improved islet survival and function with rat endothelial cells in vitro co-culture. *Transplant Proc.*, December 2009, vol. 41 (10), 4302-6 [0177]
- **SUTHERLAND DE ; GORES PF ; FARNEY AC ; WAHOFF DC ; MATAS AJ ; DUNN DL ; GRUENNER RW ; NAJARIAN JS.** Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. *Am J Surg*, 1993, vol. 166, 456-491 [0177]
- **SWEET IR ; KHALIL G ; WALLEN AR ; STEEDMAN M ; SCHENKMAN KA ; REEMS JA ; KAHN SE ; CALLIS JB.** Continuous measurement of oxygen consumption by pancreatic islets. *Diabetes Technol Ther*, 2002, vol. 4, 661-672 [0177]
- **TATARKIEWICZ K ; GARCIA M ; LOPEZ-AVALOS M ; BONNER-WEIR S ; WEIR GC.** Porcine neonatal pancreatic cell clusters in tissue culture: benefits of serum and immobilization in alginate hydrogel. *Transplantation*, 2001, vol. 71, 1518-1526 [0177]
- **VÉRITER S ; MERGEN J ; GOEBBELS RM ; AOUASSAR N ; GRÉGOIRE C ; JORDAN B ; LEVÉQUE P ; GALLEZ B ; GIANELLO P ; DUFRANE D.** In Vivo Selection of Biocompatible Alginates for Islet Encapsulation and Subcutaneous Transplantation. *Tissue Eng*, 11 February 2010 [0177]
- **VON MACH MA ; SCHLOSSER S ; WEILAND M ; FEILEN FJ ; RINGEL M ; HENGSTLER JG ; WEILEMANN LS ; BEYER J ; KANN P ; SCHNEIDER S.** Size of pancreatic islets of Langerhans: a key parameter for viability after cryopreservation. *Acta Diabetol*, 2003, vol. 40, 123-129 [0177]
- **WARNOCK GL ; ELLIS DK ; CATTRAL M ; UNTCH D ; KNETEMAN NM ; RAJOTTE RV.** Viable purified islets of Langerhans from collagenase-perfused human pancreas. *Diabetes*, 1989, vol. 38, 136-139 [0177]
- **WILLIAMS, SJ. ; WANG, MACGREGOR, R., Q. ; SI-AHAAN, T. ; STEHNO-BITTEL, L. ; BERKLAND, C.** Adhesion of pancreatic beta cells to biopolymer films. *Biopolymers*, 2009, vol. 91 (8), 676-685 [0177]
- **WILLIAMS SJ ; HUANG H ; KOVERK ; MOORE W ; BERKLAND C ; SINGH M ; STEHNO-BITTEL L.** Reduction of Diffusion Barriers in Isolated Islets Improves Survival, But Not Insulin Secretion. *Organogenesis*, 2010 [0177]
- **XU W ; MCDOUGH RC ; LANGSDORF B ; DEMAS 1N ; DEGRAFF BA.** Oxygen sensors based on luminescence quenching: interaction metal complexes with the polymer supports. *Anal Chem*, 1994, vol. 66, 4133-4141 [0177]